LT3702373T - Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai - Google Patents

Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai

Info

Publication number: LT3702373T
Authority: LT; Lithuania
Prior art keywords: therapeutics; diagnostics; antibodies
Prior art date: 2013-09-13

Application number

LTEP20154386.5T

Other languages

English (en)

Inventor

Jing Song

Kang Li

Tong Zhang

Lanlan Xu

Qi Liu

Hao PENG

Original Assignee

Beigene Switzerland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-13

Filing date

2013-09-13

Publication date

2022-11-10

2013-09-13 Application filed by Beigene Switzerland Gmbh filed Critical Beigene Switzerland Gmbh

2022-11-10 Publication of LT3702373T publication Critical patent/LT3702373T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

LTEP20154386.5T 2013-09-13 2013-09-13 Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai LT3702373T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP20154386.5A EP3702373B9 (en)	2013-09-13	2013-09-13	Anti-pd1 antibodies and their use as therapeutics and diagnostics
PCT/CN2013/083467 WO2015035606A1 (en)	2013-09-13	2013-09-13	Anti-pd1 antibodies and their use as therapeutics and diagnostics

Publications (1)

Publication Number	Publication Date
LT3702373T true LT3702373T (lt)	2022-11-10

Family

ID=50736425

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP20154386.5T LT3702373T (lt)	2013-09-13	2013-09-13	Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
LTPA2023536C LTC3702373I2 (lt)	2013-09-13	2023-12-13

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTPA2023536C LTC3702373I2 (lt)	2013-09-13	2023-12-13

Country Status (31)

Country	Link
US (10)	US8735553B1 (lt)
EP (3)	EP3702373B9 (lt)
JP (1)	JP6623353B2 (lt)
KR (1)	KR102100419B1 (lt)
CN (6)	CN112552401B (lt)
AU (3)	AU2013400609B9 (lt)
BR (1)	BR112016005408B1 (lt)
CA (3)	CA3080200A1 (lt)
CY (2)	CY1125652T1 (lt)
DK (2)	DK3702373T3 (lt)
EA (1)	EA034666B1 (lt)
ES (2)	ES2927567T3 (lt)
FI (1)	FIC20240001I1 (lt)
FR (1)	FR24C1001I2 (lt)
HR (1)	HRP20221262T1 (lt)
HU (3)	HUE049281T2 (lt)
IL (5)	IL296026B2 (lt)
LT (2)	LT3702373T (lt)
MX (1)	MX374781B (lt)
NL (1)	NL301252I2 (lt)
NO (1)	NO2023045I1 (lt)
NZ (1)	NZ718643A (lt)
PL (2)	PL3702373T3 (lt)
PT (2)	PT3702373T (lt)
RS (1)	RS63571B9 (lt)
SG (1)	SG11201601844TA (lt)
SI (1)	SI3702373T1 (lt)
SM (1)	SMT202300039T1 (lt)
TW (1)	TWI636995B (lt)
WO (1)	WO2015035606A1 (lt)
ZA (1)	ZA201601953B (lt)

Families Citing this family (698)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110229471A1 (en)	2008-11-26	2011-09-22	Cedars-Sinai Medical Center	Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010148501A1 (en)	2009-06-26	2010-12-29	Soricimed Biopharma Inc.	Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
CA3027071A1 (en)	2011-01-14	2013-07-19	The Regents Of The University Of California	Therapeutic antibodies against ror-1 protein and methods for use of same
EP3409278B8 (en)	2011-07-21	2020-11-04	Sumitomo Dainippon Pharma Oncology, Inc.	Heterocyclic protein kinase inhibitors
ME02855B (me)	2011-12-31	2018-04-20	Beigene Ltd	KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI
JP6671276B2 (ja)	2013-03-27	2020-03-25	セダーズ−シナイメディカルセンター	Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
BR112015025260B1 (pt)	2013-04-25	2021-11-03	Beigene, Ltd	Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
EP4105236A1 (en)	2013-07-19	2022-12-21	Cedars-Sinai Medical Center	Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
JP6521977B2 (ja)	2013-09-06	2019-05-29	オーリジーンディスカバリーテクノロジーズリミテッドＡｕｒｉｇｅｎｅＤｉｓｃｏｖｅｒｙＴｅｃｈｎｏｌｏｇｉｅｓＬｉｍｉｔｅｄ	免疫調節剤としての１，２，４−オキサジアゾール誘導体
KR20160075506A (ko)	2013-09-06	2016-06-29	오리진 디스커버리 테크놀로지스 리미티드	면역조절제로서 사이클릭 펩티도미메틱 화합물
JP2016532711A (ja)	2013-09-06	2016-10-20	オーリジーンディスカバリーテクノロジーズリミテッドＡｕｒｉｇｅｎｅＤｉｓｃｏｖｅｒｙＴｅｃｈｎｏｌｏｇｉｅｓＬｉｍｉｔｅｄ	免疫調節剤としての１，３，４−オキサジアゾール及び１，３，４−チアジアゾールの誘導体
RS63571B9 (sr)	2013-09-13	2023-02-28	Beigene Switzerland Gmbh	Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
PL3081576T3 (pl)	2013-12-12	2020-03-31	Shanghai Hengrui Pharmaceutical Co., Ltd.	Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
RU2732604C2 (ru)	2013-12-20	2020-09-21	Интервет Интернэшнл Б.В.	Антитела к pd-1 собак
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10618963B2 (en)	2014-03-12	2020-04-14	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN114081946A (zh)	2014-03-12	2022-02-25	耶达研究与开发有限公司	降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US10519237B2 (en)	2014-03-12	2019-12-31	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en)	2014-03-12	2016-07-19	Yeda Research And Development Co., Ltd	Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
EP3660050A1 (en)	2014-03-14	2020-06-03	Novartis AG	Antibody molecules to lag-3 and uses thereof
TWI693232B (zh)	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10544225B2 (en) *	2014-07-03	2020-01-28	Beigene, Ltd.	Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
CN106573052B (zh) *	2014-07-22	2021-04-06	中美冠科生物技术（太仓）有限公司	抗pd-1抗体
KR102357893B1 (ko) *	2014-08-05	2022-02-04	맵퀘스트 에스아	Pd-1 에 결합하는 면역학적 시약
WO2016022630A1 (en)	2014-08-05	2016-02-11	Jiping Zha	Anti-pd-l1 antibodies
US9982052B2 (en)	2014-08-05	2018-05-29	MabQuest, SA	Immunological reagents
US20170239351A1 (en)	2014-08-11	2017-08-24	Acerta Pharma B.V.	Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
ES2727137T3 (es)	2014-08-28	2019-10-14	Halozyme Inc	Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
TW201617368A (zh)	2014-09-05	2016-05-16	史坦森特瑞斯公司	新穎抗ｍｆｉ２抗體及使用方法
KR20170060042A (ko)	2014-09-13	2017-05-31	노파르티스 아게	Alk 억제제의 조합 요법
KR102122463B1 (ko)	2014-10-14	2020-06-15	할로자임, 아이엔씨	아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
JP7305300B2 (ja)	2014-11-05	2023-07-10	ザリージェンツオブザユニバーシティオブカリフォルニア	併用免疫療法
WO2016077397A2 (en) *	2014-11-11	2016-05-19	Sutro Biopharma, Inc.	Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
HRP20201756T8 (hr)	2014-11-21	2021-08-20	Bristol-Myers Squibb Company	Antitijela koja sadrže modificirane regije teškog lanca
TWI711630B (zh)	2014-11-21	2020-12-01	美商必治妥美雅史谷比公司	抗ｃｄ７３抗體及其用途
EP3237446B1 (en) *	2014-12-22	2021-05-05	PD-1 Acquisition Group, LLC	Anti-pd-1 antibodies
US11639385B2 (en)	2014-12-22	2023-05-02	Pd-1 Acquisition Group, Llc	Anti-PD-1 antibodies
US10509033B2 (en) *	2015-01-20	2019-12-17	Kyushu University, National University Corporation	Method, kit and biomarker for diagnosing chronic inflammatory demyelinating polyneuropathy
SMT202200163T1 (it)	2015-03-10	2022-05-12	Aurigene Discovery Tech Ltd	Composti di 1,2,4-0ssadiazolo e tiadiazolo come immunomodulatori
WO2016149201A2 (en)	2015-03-13	2016-09-22	Cytomx Therapeutics, Inc.	Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
RS59878B1 (sr)	2015-03-23	2020-03-31	Bayer Pharma AG	Anti-ceacam6 antitela i njihova primena
CN106146667B (zh) *	2015-03-27	2020-06-19	四川大学华西医院	一种Exendin-4融合蛋白及其制备方法与用途
US11933786B2 (en)	2015-03-30	2024-03-19	Stcube, Inc.	Antibodies specific to glycosylated PD-L1 and methods of use thereof
CN114380909A (zh)	2015-03-30	2022-04-22	斯特库比股份有限公司	特异性针对糖基化的pd-l1的抗体及其使用方法
EP3277716B1 (en)	2015-04-03	2020-06-24	XOMA Technology Ltd.	Treatment of cancer using inhibitors of tgf-beta and pd-1
GB201506411D0 (en)	2015-04-15	2015-05-27	Bergenbio As	Humanized anti-axl antibodies
KR20250004095A (ko)	2015-04-17	2025-01-07	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
WO2016176504A1 (en)	2015-04-28	2016-11-03	Bristol-Myers Squibb Company	Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
KR20170138555A (ko)	2015-04-28	2017-12-15	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
RU2017142352A (ru)	2015-05-06	2019-06-06	Снипр Текнолоджиз Лимитед	Изменение популяций микроорганизмов и модификация микробиоты
WO2016179472A2 (en) *	2015-05-07	2016-11-10	University Of Maryland, Baltimore	Modulation of natural killer cell tolerance
EP4086264B1 (en)	2015-05-18	2023-10-25	Sumitomo Pharma Oncology, Inc.	Alvocidib prodrugs having increased bioavailability
KR20190080992A (ko)	2015-05-21	2019-07-08	하푼 테라퓨틱스, 인크.	삼중특이성 결합 단백질 및 사용 방법
US20180155429A1 (en)	2015-05-28	2018-06-07	Bristol-Myers Squibb Company	Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
SI3303394T1 (sl)	2015-05-29	2020-10-30	Agenus Inc.	Protitelesa proti-CTLA-4 in postopki njihove uporabe
WO2016196389A1 (en)	2015-05-29	2016-12-08	Bristol-Myers Squibb Company	Treatment of renal cell carcinoma
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
CN105061597B (zh) *	2015-06-09	2016-04-27	北京东方百泰生物科技有限公司	一种抗pd-1的单克隆抗体及其获得方法
BR112018000768A2 (pt) *	2015-07-13	2018-09-25	Cytomx Therapeutics Inc	anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
SMT202100131T1 (it)	2015-07-14	2021-05-07	Bristol Myers Squibb Co	Metodo di trattamento di un cancro usando un inibitore di checkpoint immunitari; anticorpo che si lega al recettore della morte programmata-1 (pd-1) o al ligando della morte programmata 1 (pd-l1)
NZ739503A (en)	2015-07-16	2023-06-30	Bioxcel Therapeutics Inc	A novel approach for treatment of cancer using immunomodulation
SG10202010506TA (en)	2015-07-30	2020-11-27	Macrogenics Inc	Pd-1-binding molecules and methods of use thereof
JP2018526989A (ja)	2015-08-07	2018-09-20	ピエリスファーマシューティカルズゲーエムベーハー	Ｌａｇ−３およびｐｄ−１に特異的な新規融合ポリペプチド
WO2017024465A1 (en)	2015-08-10	2017-02-16	Innovent Biologics (Suzhou) Co., Ltd.	Pd-1 antibodies
JP6940039B2 (ja)	2015-08-25	2021-09-22	ベイジーンリミテッド	Ｐａｒｐ阻害剤の製造方法、結晶型、及びその使用
CN107949573B (zh) *	2015-09-01	2022-05-03	艾吉纳斯公司	抗-pd-1抗体及其使用方法
MA44909A (fr)	2015-09-15	2018-07-25	Acerta Pharma Bv	Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
ES2839212T3 (es)	2015-09-29	2021-07-05	Inst Nat Sante Rech Med	Métodos para determinar el estado metabólico de linfomas B
KR20180054824A (ko) *	2015-09-29	2018-05-24	셀진 코포레이션	Pd-1 결합 단백질 및 이의 사용 방법
CA3000638C (en) *	2015-09-29	2024-02-27	Asia Biotech Pte. Ltd.	Pd-1 antibodies and uses thereof
IL295423B2 (en)	2015-10-01	2023-11-01	Heat Biologics Inc	Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins
US12030942B2 (en)	2015-10-02	2024-07-09	Les Laboratoires Servier	Anti-PD-1 antibodies and compositions
CN106632674B (zh) *	2015-10-30	2018-11-16	泽达生物医药有限公司	一种抗pd-1单克隆抗体、其药物组合物及其用途
WO2017079202A1 (en)	2015-11-02	2017-05-11	Board Of Regents, The University Of Texas System	Methods of cd40 activation and immune checkpoint blockade
MY198562A (en)	2015-11-03	2023-09-05	Janssen Biotech Inc	Antibodies specifically binding pd-1 and their uses
WO2017079746A2 (en)	2015-11-07	2017-05-11	Multivir Inc.	Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CN106699889A (zh) *	2015-11-18	2017-05-24	礼进生物医药科技（上海）有限公司	抗pd-1抗体及其治疗用途
PT3377534T (pt)	2015-11-18	2025-07-10	Bristol Myers Squibb Co	Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4
EP3383412A4 (en) *	2015-12-02	2019-06-05	Stcube, Inc.	SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF
US10954301B2 (en)	2015-12-14	2021-03-23	Macrogenics, Inc.	Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
US10392442B2 (en)	2015-12-17	2019-08-27	Bristol-Myers Squibb Company	Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
CA3005696A1 (en)	2015-12-18	2017-06-22	Intervet International B.V.	Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en)	2015-12-18	2021-08-17	Intervet Inc.	Caninized human antibodies to human IL-4R alpha
PL3394093T3 (pl)	2015-12-23	2022-05-16	Modernatx, Inc.	Metody stosowania polinukleotydów kodujących ligand ox40
WO2017118634A1 (en)	2016-01-04	2017-07-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
WO2017122175A1 (en)	2016-01-13	2017-07-20	Acerta Pharma B.V.	Therapeutic combinations of an antifolate and a btk inhibitor
CN109069628A (zh) *	2016-01-14	2018-12-21	Bps生物科学有限公司	抗pd-1抗体及其用途
EP3195878A1 (en)	2016-01-22	2017-07-26	Werner Lubitz	Bacterial ghosts for the treatment of cancer
DK3964529T3 (da)	2016-01-22	2025-06-30	MabQuest SA	Ikke-blokerende pd1-specifikke antistoffer
US11214617B2 (en)	2016-01-22	2022-01-04	MabQuest SA	Immunological reagents
CU20180088A7 (es)	2016-02-17	2019-05-03	Novartis Ag	Anticuerpos anti tgfbeta 2
US11186872B2 (en)	2016-03-17	2021-11-30	Cedars-Sinai Medical Center	Methods of diagnosing inflammatory bowel disease through RNASET2
WO2017165742A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
JP7241541B2 (ja)	2016-03-29	2023-03-17	エスティーキューブ，インコーポレイテッド	グリコシル化ｐｄ－ｌ１に特異的な二重機能抗体およびその使用方法
JP7572146B2 (ja)	2016-03-29	2024-10-23	エスティーキューブアンドカンパニー，インコーポレイテッド	グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
US11046782B2 (en)	2016-03-30	2021-06-29	Musc Foundation For Research Development	Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
WO2017176925A1 (en)	2016-04-05	2017-10-12	Bristol-Myers Squibb Company	Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
DK3449017T3 (da)	2016-04-29	2022-03-14	Univ Texas	Målrettet måling af transkriptionel aktivitet vedrørende hormonreceptorer
WO2017200796A1 (en)	2016-05-17	2017-11-23	Albert Einstein College Of Medicine, Inc.	Engineered pd-1 variants
DK3458083T5 (da)	2016-05-18	2024-10-21	Modernatx Inc	Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
LT3458474T (lt)	2016-05-18	2022-10-10	Modernatx, Inc.	Imunitetą moduliuojančius polipeptidus koduojančių mrnr deriniai ir jų naudojimas
MA45037A (fr)	2016-05-18	2019-03-27	Modernatx Inc	Polythérapie à base d'arnm pour le traitement du cancer
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
CN105968200B (zh)	2016-05-20	2019-03-15	瑞阳(苏州)生物科技有限公司	抗人pd-l1人源化单克隆抗体及其应用
CN106008714B (zh)	2016-05-24	2019-03-15	瑞阳(苏州)生物科技有限公司	抗人pd-1人源化单克隆抗体及其应用
TWI895621B (zh)	2016-05-27	2025-09-01	美商艾吉納斯公司	抗-tim-3抗體及其使用方法
FI3464368T3 (fi)	2016-06-02	2023-09-12	Bristol Myers Squibb Co	Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa
KR20190015377A (ko)	2016-06-02	2019-02-13	브리스톨-마이어스 스큅 컴퍼니	불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단
EP3464369A1 (en)	2016-06-03	2019-04-10	Bristol-Myers Squibb Company	Anti-pd-1 antibody for use in a method of treating a tumor
US20190292260A1 (en)	2016-06-03	2019-09-26	Bristol-Myers Squibb Company	Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
WO2017210637A1 (en)	2016-06-03	2017-12-07	Bristol-Myers Squibb Company	Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
GB201609811D0 (en)	2016-06-05	2016-07-20	Snipr Technologies Ltd	Methods, cells, systems, arrays, RNA and kits
WO2017214182A1 (en) *	2016-06-07	2017-12-14	The United States Of America. As Represented By The Secretary, Department Of Health & Human Services	Fully human antibody targeting pdi for cancer immunotherapy
US11472856B2 (en)	2016-06-13	2022-10-18	Torque Therapeutics, Inc.	Methods and compositions for promoting immune cell function
AU2017286128B2 (en) *	2016-06-17	2022-02-24	The Trustees Of The University Of Pennsylvania	Compounds, compositions and methods for prevention and/or treatment of cancer
JP7461741B2 (ja)	2016-06-20	2024-04-04	カイマブ・リミテッド	抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
EP3476865B1 (en)	2016-06-28	2023-09-13	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Method for constructing pd-1 gene-modified humanized animal model and use thereof
WO2018007885A1 (en) *	2016-07-05	2018-01-11	Beigene, Ltd.	COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
RU2656181C1 (ru) *	2016-07-13	2018-05-31	Закрытое Акционерное Общество "Биокад"	Анти-pd-1-антитела, способ их получения и способ применения
EP3487883B1 (en)	2016-07-20	2023-01-04	Stcube, Inc.	Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
JP7402685B2 (ja)	2016-08-16	2023-12-21	ベイジーンスウィッツァーランドゲーエムベーハー	（ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
AU2017313085B2 (en)	2016-08-19	2024-06-20	Beone Medicines I Gmbh	Use of a combination comprising a Btk inhibitor for treating cancers
WO2018039131A1 (en)	2016-08-22	2018-03-01	Protiva Biotherapeutics, Inc.	Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
SG10201912199XA (en)	2016-08-26	2020-02-27	Beigene Ltd	Anti-tim-3 antibodies and use thereof
EP4342978A3 (en)	2016-09-01	2024-07-03	Chimera Bioengineering Inc.	Gold optimized car t-cells
US12298309B2 (en)	2016-09-06	2025-05-13	Incelldx, Inc.	Methods of assaying neoplastic and neoplasia-related cells and uses thereof
US11726089B2 (en)	2016-09-06	2023-08-15	Incelldx, Inc.	Methods of assaying neoplastic and neoplasia-related cells and uses thereof
SG11201901991QA (en)	2016-09-06	2019-04-29	Incelldx Inc	Methods of detecting per cell pd-l1 expression and uses thereof
WO2018049226A1 (en)	2016-09-08	2018-03-15	Bluebird Bio, Inc.	Pd-1 homing endonuclease variants, compositions, and methods of use
JP7164528B2 (ja)	2016-09-14	2022-11-01	ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド	Ｐｄ－１に特異的に結合する可能な抗体及びその機能的断片
BR112019004733A2 (pt)	2016-09-19	2019-05-28	Celgene Corp	métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
US10766958B2 (en)	2016-09-19	2020-09-08	Celgene Corporation	Methods of treating vitiligo using PD-1 binding antibodies
CN107840887B (zh) *	2016-09-21	2022-03-25	基石药业（苏州）有限公司	一种新的pd-1单克隆抗体
BR112019006041A2 (pt)	2016-09-27	2019-09-03	Board Of Regents, The University Of Texas System	métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
US11202782B2 (en)	2016-09-27	2021-12-21	Beigene, Ltd.	Treatment cancers using a combination comprising PARP inhibitors
KR102576042B1 (ko)	2016-10-11	2023-09-07	아게누스 인코포레이티드	항-lag-3 항체 및 이의 사용 방법
SG11201903283UA (en)	2016-10-12	2019-05-30	Univ Texas	Methods and compositions for tusc2 immunotherapy
KR20190082815A (ko)	2016-10-26	2019-07-10	세다르스-신나이 메디칼 센터	중화 항-tl1a 단일 클론 항체
EP4491237A3 (en)	2016-10-28	2025-03-26	Bristol-Myers Squibb Company	Methods of treating urothelial carcinoma using an anti-pd-1 antibody
TWI788307B (zh)	2016-10-31	2023-01-01	美商艾歐凡斯生物治療公司	用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
BR112019008494A2 (pt)	2016-11-02	2019-07-09	Jounce Therapeutics Inc	anticorpos para pd-1 e usos dos mesmos
CA3042679A1 (en)	2016-11-03	2018-05-11	Bristol-Myers Squibb Company	Activatable anti-ctla-4 antibodies and uses thereof
WO2018089423A1 (en)	2016-11-09	2018-05-17	Musc Foundation For Research Development	Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
KR102771603B1 (ko)	2016-11-17	2025-02-24	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
EA201991214A1 (ru) *	2016-11-18	2019-10-31		Антитела против pd-1 и их композиции
US11279694B2 (en)	2016-11-18	2022-03-22	Sumitomo Dainippon Pharma Oncology, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en)	2016-11-22	2018-05-31	Jun Oishi	Targeting kras induced immune checkpoint expression
IL266918B2 (en)	2016-12-07	2024-03-01	Agenus Inc	Anti-ctla-4 antibodies and methods of use thereof
JP7106538B2 (ja)	2016-12-07	2022-07-26	アジェナスインコーポレイテッド	抗体およびその使用方法
JP2020510624A (ja)	2016-12-12	2020-04-09	マルチビアインコーポレイテッド	がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
CN106519034B (zh) *	2016-12-22	2020-09-18	鲁南制药集团股份有限公司	抗pd-1抗体及其用途
CN113480530A (zh)	2016-12-26	2021-10-08	阿里根公司	芳香烃受体调节剂
US11584733B2 (en)	2017-01-09	2023-02-21	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
ES2914123T3 (es)	2017-01-09	2022-06-07	Shuttle Pharmaceuticals Inc	Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
MA47265A (fr)	2017-01-13	2019-11-20	Agenus Inc	Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers
WO2018134279A1 (en)	2017-01-18	2018-07-26	Pieris Pharmaceuticals Gmbh	Novel fusion polypeptides specific for lag-3 and pd-1
WO2018134784A1 (en)	2017-01-20	2018-07-26	Novartis Ag	Combination therapy for the treatment of cancer
CN117586401A (zh)	2017-01-20	2024-02-23	大有华夏生物医药集团有限公司	抗pd-1抗体及其用途
EP3571227A1 (en)	2017-01-20	2019-11-27	Sanofi	Anti-tgf-beta antibodies and their use
TW202421659A (zh)	2017-01-20	2024-06-01	美商健臻公司	骨靶向抗體
TWI856437B (zh)	2017-01-20	2024-09-21	法商賽諾菲公司	抗TGF-β抗體及其用途
CN108341871A (zh)	2017-01-24	2018-07-31	三生国健药业（上海）股份有限公司	抗pd-1单克隆抗体及其制备方法和应用
CN110461847B (zh)	2017-01-25	2022-06-07	百济神州有限公司	(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
WO2018146612A1 (en)	2017-02-10	2018-08-16	Novartis Ag	1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
TWI674261B (zh)	2017-02-17	2019-10-11	美商英能腫瘤免疫股份有限公司	Nlrp3 調節劑
CN110612447B (zh)	2017-02-24	2024-02-06	德克萨斯州立大学董事会	用于检测早期胰腺癌的测定
IL313003A (en)	2017-02-27	2024-07-01	Shattuck Labs Inc	Tigit- and light-based chimeric proteins
CN110337305A (zh)	2017-02-28	2019-10-15	赛诺菲	治疗性rna
CN110392687B (zh)	2017-02-28	2022-08-02	百济神州(苏州)生物科技有限公司	稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US11161905B2 (en)	2017-03-04	2021-11-02	Xiangtan Tenghua Bioscience	Recombinant antibodies to programmed death 1 (PD-1) and uses thereof
US20200095323A1 (en) *	2017-03-20	2020-03-26	The General Hospital Corporation	MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
WO2018172508A1 (en)	2017-03-24	2018-09-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
CN107082812B (zh)	2017-03-29	2018-11-13	上海科医联创生物科技有限公司	一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
CA3058175A1 (en)	2017-03-31	2018-10-04	Bristol-Myers Squibb Company	Methods of treating tumor
JP2020513009A (ja)	2017-04-05	2020-04-30	シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎＡ／Ｓ	Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
CA3059366A1 (en)	2017-04-13	2018-10-18	Agenus Inc.	Anti-cd137 antibodies and methods of use thereof
CN106939049B (zh)	2017-04-20	2019-10-01	苏州思坦维生物技术股份有限公司	拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
US11492403B2 (en)	2017-04-20	2022-11-08	Dana-Farber Cancer Institute, Inc.	Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof
CA3057748A1 (en)	2017-04-20	2018-10-25	Adc Therapeutics Sa	Combination therapy with an anti-axl antibody-drug conjugate
JP7402691B2 (ja)	2017-04-20	2023-12-21	アーデーセーセラピューティクスソシエテアノニム	抗ｃｄ２５抗体薬物複合体による併用療法
AR111651A1 (es)	2017-04-28	2019-08-07	Novartis Ag	Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JP7257967B2 (ja) *	2017-05-01	2023-04-14	ザチルドレンズメディカルセンターコーポレーション	抗ｐｄ１抗体試薬に関する方法および組成物
LT3618863T (lt)	2017-05-01	2023-10-10	Agenus Inc.	Anti-tigit antikūnai ir jų panaudojimo būdai
SG10202107880XA (en)	2017-05-12	2021-09-29	Harpoon Therapeutics Inc	Mesothelin binding proteins
CA3063723A1 (en)	2017-05-18	2018-11-22	Modernatx, Inc.	Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
AR111760A1 (es)	2017-05-19	2019-08-14	Novartis Ag	Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
AU2018277824A1 (en)	2017-05-30	2019-10-17	Bristol-Myers Squibb Company	Treatment of LAG-3 positive tumors
MX2019012076A (es)	2017-05-30	2019-12-09	Bristol Myers Squibb Co	Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
EP3630842A2 (en)	2017-05-30	2020-04-08	Bristol-Myers Squibb Company	Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
JOP20190279A1 (ar)	2017-05-31	2019-11-28	Novartis Ag	الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
BR112019025035A2 (pt)	2017-06-01	2020-06-30	Compugen Ltd.	método para tratar câncer
CN110914302A (zh)	2017-06-01	2020-03-24	赛托姆克斯治疗学股份有限公司	可活化抗pdl1抗体及其使用方法
US11566073B2 (en)	2017-06-01	2023-01-31	Bristol-Myers Squibb Company	Methods of treating a tumor using an anti-PD-1 antibody
ES2988683T3 (es)	2017-06-14	2024-11-21	Adc Therapeutics Sa	Pautas posológicas para la administración de un CAF anti-CD19
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018234879A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Il-1beta binding antibodies for use in treating cancer
WO2018235056A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Il-1beta binding antibodies for use in treating cancer
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
KR20200021087A (ko)	2017-06-22	2020-02-27	노파르티스 아게	Cd73에 대한 항체 분자 및 이의 용도
WO2019001417A1 (en) *	2017-06-26	2019-01-03	Beigene, Ltd.	IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
JP2020525483A (ja)	2017-06-27	2020-08-27	ノバルティスアーゲー	抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
EP3421494A1 (en)	2017-06-29	2019-01-02	Sanofi	Use of isatuximab in combination with an anti-pd-1 antibody
SG11202000248UA (en)	2017-07-14	2020-02-27	Innate Tumor Immunity Inc	Nlrp3 modulators
CN111163798A (zh)	2017-07-20	2020-05-15	诺华股份有限公司	用于抗lag-3抗体的给药方案及其用途
WO2019023624A1 (en)	2017-07-28	2019-01-31	Bristol-Myers Squibb Company	PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR INHIBITORS OF CONTROL POINTS
JP7186764B2 (ja)	2017-07-28	2022-12-09	ブリストル－マイヤーズスクイブカンパニー	抗癌剤としての環状ジヌクレオチド
US11377449B2 (en)	2017-08-12	2022-07-05	Beigene, Ltd.	BTK inhibitors with improved dual selectivity
KR20200044899A (ko)	2017-08-28	2020-04-29	브리스톨-마이어스 스큅 컴퍼니	암의 치료 및 진단을 위한 tim-3 길항제
US10953032B2 (en)	2017-08-31	2021-03-23	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
JP7316263B2 (ja)	2017-08-31	2023-07-27	ブリストル－マイヤーズスクイブカンパニー	抗癌剤としての環状ジヌクレオチド
CN111051327B (zh)	2017-08-31	2023-11-03	百时美施贵宝公司	作为抗癌剂的环二核苷酸
JP7387585B2 (ja)	2017-09-04	2023-11-28	アジェナスインコーポレイテッド	混合系統白血病（ｍｌｌ）特異的ホスホペプチドに結合するｔ細胞受容体およびその使用方法
JP7196160B2 (ja)	2017-09-12	2022-12-26	スミトモファーマオンコロジー，インコーポレイテッド	Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
EP3691643A4 (en)	2017-09-29	2021-06-16	Bristol-Myers Squibb Company	COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
WO2019061324A1 (en)	2017-09-29	2019-04-04	Curis Inc.	CRYSTALLINE FORMS OF IMMUNOMODULATORS
EP3694867B1 (en)	2017-10-10	2025-12-24	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
US11136300B2 (en)	2017-10-11	2021-10-05	Aurigene Discovery Technologies Limited	Crystalline forms of 3-substituted 1,2,4-oxadiazole
WO2019075385A1 (en)	2017-10-12	2019-04-18	Board Of Regents, The University Of Texas System	T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
PL3694529T3 (pl)	2017-10-13	2024-12-16	Harpoon Therapeutics, Inc.	Trójswoiste białka i sposoby zastosowania
WO2019072241A1 (en)	2017-10-13	2019-04-18	Beijing Biocytogen Co., Ltd	NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
KR101982001B1 (ko) *	2017-10-13	2019-05-27	한국과학기술원	동종 또는 이종 거부반응을 이용한 항 pd-1 또는 항 pd-l1 항체 선별 방법
JP2020536894A (ja)	2017-10-15	2020-12-17	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	腫瘍処置法
EP3697801B1 (en)	2017-10-16	2024-11-20	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
EP3700933A1 (en)	2017-10-25	2020-09-02	Novartis AG	Antibodies targeting cd32b and methods of use thereof
JP7378394B2 (ja)	2017-11-03	2023-11-13	オーリジーンオンコロジーリミテッド	Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
WO2019087092A1 (en)	2017-11-06	2019-05-09	Aurigene Discovery Technologies Limited	Conjoint therapies for immunomodulation
CN111315397A (zh)	2017-11-06	2020-06-19	百时美施贵宝公司	治疗肿瘤的方法
JP7544597B2 (ja)	2017-11-06	2024-09-03	ジェネンテック，インコーポレイテッド	がんの診断及び療法
CA3079999A1 (en)	2017-11-07	2019-05-16	The Board Of Regents Of The University Of Texas System	Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
WO2019094265A1 (en) *	2017-11-10	2019-05-16	Armo Biosciences, Inc.	Pd1 polypeptide binding molecules
US11529344B2 (en)	2017-11-14	2022-12-20	Pfizer Inc.	EZH2 inhibitor combination therapies
RU2020119578A (ru)	2017-11-16	2021-12-17	Новартис Аг	Комбинированные терапии
CN111587249A (zh)	2017-11-20	2020-08-25	阿里根公司	吲哚化合物及其用途
CN107952069A (zh) *	2017-11-24	2018-04-24	长春百克生物科技股份公司	重组疫苗及其应用
US11786529B2 (en)	2017-11-29	2023-10-17	Beigene Switzerland Gmbh	Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
SG11202005005YA (en)	2017-11-30	2020-06-29	Novartis Ag	Bcma-targeting chimeric antigen receptor, and uses thereof
US11667713B2 (en) *	2017-12-28	2023-06-06	Chugai Seiyaku Kabushiki Kaisha	Cytotoxicity-inducing therapeutic agent
EP3735590A1 (en)	2018-01-04	2020-11-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma resistant
EP3737408A1 (en)	2018-01-08	2020-11-18	Novartis AG	Immune-enhancing rnas for combination with chimeric antigen receptor therapy
ES2983284T3 (es)	2018-01-09	2024-10-22	Shuttle Pharmaceuticals Inc	Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas
KR102839330B1 (ko) *	2018-01-15	2025-07-30	난징 레전드 바이오테크 씨오., 엘티디.	Pd-1에 대한 단일-도메인 항체 및 이의 변이체
EP3740506A1 (en)	2018-01-16	2020-11-25	Bristol-Myers Squibb Company	Methods of treating cancer with antibodies against tim3
MX2020007526A (es)	2018-01-22	2020-09-09	Bristol Myers Squibb Co	Composiciones y metodos para tratar el cancer.
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
AU2019210332A1 (en)	2018-01-22	2020-09-10	Pascal Biosciences Inc.	Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
AU2019215031B2 (en)	2018-01-31	2025-10-09	Novartis Ag	Combination therapy using a chimeric antigen receptor
US20200405806A1 (en)	2018-02-08	2020-12-31	Bristol-Myers Squibb Company	Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
EP3749366A4 (en) *	2018-02-09	2021-11-10	BeiGene, Ltd.	IMMUNOTHERAPY FOR UROTHELIAL CARCINOMA
US20200399383A1 (en)	2018-02-13	2020-12-24	Novartis Ag	Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en)	2018-02-13	2019-12-31	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
WO2019162325A1 (en)	2018-02-21	2019-08-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
WO2019161536A1 (en)	2018-02-23	2019-08-29	Eucure (Beijing) Biopharma Co. , Ltd	Anti-pd-1 antibodies and uses thereof
WO2019173587A1 (en)	2018-03-08	2019-09-12	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
GB201803746D0 (en) *	2018-03-08	2018-04-25	Ultrahuman Eight Ltd	PD1 binding agents
GB201803745D0 (en)	2018-03-08	2018-04-25	Ultrahuman Eight Ltd	PD1 binding agents
WO2020036635A2 (en)	2018-03-19	2020-02-20	Multivir Inc.	Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
TWI841554B (zh)	2018-03-21	2024-05-11	丹麥商珍美寶股份有限公司	以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
PE20210665A1 (es)	2018-03-23	2021-03-31	Bristol Myers Squibb Co	Anticuerpos contra mica y/o micb y sus usos
US10760075B2 (en)	2018-04-30	2020-09-01	Snipr Biome Aps	Treating and preventing microbial infections
KR20210006344A (ko)	2018-03-25	2021-01-18	에스엔아이피알 바이옴 에이피에스.	미생물 감염의 치료 및 예방
BR112020019251A2 (pt)	2018-03-27	2021-01-12	Board Of Regents, The University Of Texas System	Compostos com atividade anti-tumor contra células de câncer com mutações de her2 exon 19
EP3774911A1 (en)	2018-03-30	2021-02-17	Bristol-Myers Squibb Company	Methods of treating tumor
EP3774903A1 (en)	2018-04-04	2021-02-17	Bristol-Myers Squibb Company	Anti-cd27 antibodies and uses thereof
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN112585165B8 (zh)	2018-04-25	2025-02-14	普罗米修斯生物科学公司	优化的抗tl1a抗体
BR112020021539A2 (pt)	2018-04-25	2021-01-19	Innate Tumor Immunity, Inc.	Moduladores de nlrp3
US11957695B2 (en)	2018-04-26	2024-04-16	The Broad Institute, Inc.	Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210055A2 (en)	2018-04-26	2019-10-31	Agenus Inc.	Heat shock protein-binding peptide compositions and methods of use thereof
US20210386829A1 (en)	2018-05-04	2021-12-16	The Broad Institute, Inc.	Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
CN112739716B (zh)	2018-05-07	2025-05-27	展马博联合股份有限公司	使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
BR112020022265A2 (pt)	2018-05-07	2021-02-23	Genmab A/S	método para tratar câncer em um indivíduo, e, estojo.
US11136394B2 (en)	2018-05-17	2021-10-05	Nanjing Leads Biolabs Co., Ltd.	Antibody binding PD-1 and use thereof
CN112566935B (zh)	2018-05-23	2024-12-13	百济神州有限公司	抗ox40抗体和使用方法
BR112020023846A2 (pt)	2018-05-23	2021-04-13	Adc Therapeutics Sa	Adjuvante molecular
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
EP3810109B1 (en)	2018-05-31	2024-08-07	Peloton Therapeutics, Inc.	Compounds and compositions for inhibiting cd73
JP7398396B2 (ja)	2018-06-01	2023-12-14	ノバルティスアーゲー	Ｂｃｍａに対する結合分子及びその使用
CN114031682B (zh) *	2018-06-07	2023-06-30	江苏东抗生物医药科技有限公司	一种高亲和力的pd-1膜外区突变体的融合蛋白及其药物组合物和用途
CA3103610A1 (en)	2018-06-12	2019-12-19	The Regents Of The University Of California	Single-chain bispecific chimeric antigen receptors for the treatment of cancer
EP4349411A3 (en)	2018-06-20	2024-06-19	Incyte Corporation	Anti-pd-1 antibodies and uses thereof
SG11202012446UA (en)	2018-06-23	2021-01-28	Genentech Inc	Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PL3820573T3 (pl)	2018-07-10	2024-02-19	Novartis Ag	Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
AU2019302642B2 (en)	2018-07-10	2025-10-30	Regeneron Pharmaceuticals, Inc.	Modifying binding molecules to minimize pre-existing interactions
JP7340591B2 (ja)	2018-07-11	2023-09-07	アクティム・セラピューティクス・インコーポレイテッド	遺伝子操作された免疫刺激性細菌菌株およびその使用
WO2020014583A1 (en)	2018-07-13	2020-01-16	Bristol-Myers Squibb Company	Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
EP3823611A1 (en)	2018-07-18	2021-05-26	Genentech, Inc.	Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
CN112424231B (zh) *	2018-07-19	2022-09-13	大有华夏生物医药集团有限公司	抗pd-1抗体及其剂量和用途
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
AU2019309849A1 (en)	2018-07-26	2021-03-18	Bristol-Myers Squibb Company	LAG-3 combination therapy for the treatment of cancer
WO2020021061A1 (en)	2018-07-26	2020-01-30	Pieris Pharmaceuticals Gmbh	Humanized anti-pd-1 antibodies and uses thereof
WO2020037091A1 (en)	2018-08-16	2020-02-20	Innate Tumor Immunity, Inc.	Imidazo[4,5-c]quinoline derived nlrp3-modulators
MX2021001581A (es)	2018-08-16	2021-04-19	Innate Tumor Immunity Inc	Compuestos de 4-amino-1h-imidazo[4,5-c]quinolina sustituidos y metodos mejorados para su preparacion.
WO2020037092A1 (en)	2018-08-16	2020-02-20	Innate Tumor Immunity, Inc.	Imidazo[4,5-c]quinoline derived nlrp3-modulators
WO2020041655A1 (en)	2018-08-24	2020-02-27	Sanofi	Therapeutic rna for solid tumor cancers
CN112955221A (zh)	2018-08-27	2021-06-11	皮里斯制药有限公司	包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
US10780121B2 (en)	2018-08-29	2020-09-22	Shattuck Labs, Inc.	FLT3L-based chimeric proteins
WO2020044252A1 (en)	2018-08-31	2020-03-05	Novartis Ag	Dosage regimes for anti-m-csf antibodies and uses thereof
TW202031273A (zh)	2018-08-31	2020-09-01	美商艾歐凡斯生物治療公司	抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
CN112805267B (zh)	2018-09-03	2024-03-08	豪夫迈·罗氏有限公司	用作tead调节剂的甲酰胺和磺酰胺衍生物
WO2020049534A1 (en)	2018-09-07	2020-03-12	Novartis Ag	Sting agonist and combination therapy thereof for the treatment of cancer
WO2020061376A2 (en)	2018-09-19	2020-03-26	Alpine Immune Sciences, Inc.	Methods and uses of variant cd80 fusion proteins and related constructs
MX2021002887A (es)	2018-09-20	2021-06-04	Iovance Biotherapeutics Inc	Expansion de linfocitos infiltrantes de tumores (tils) a partir de muestras de tumor crioconservadas.
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
CN113286817B (zh)	2018-09-25	2025-01-28	哈普恩治疗公司	Dll3结合蛋白及使用方法
JP2022512642A (ja)	2018-10-09	2022-02-07	ブリストル－マイヤーズスクイブカンパニー	がんを治療するための抗ＭｅｒＴＫ抗体
US20210348238A1 (en)	2018-10-16	2021-11-11	Novartis Ag	Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
CN109470806A (zh) *	2018-10-19	2019-03-15	张骐	通过二维液相对单抗类产品细胞株进行高通量筛选的方法
ES2986921T3 (es)	2018-10-19	2024-11-13	Bristol Myers Squibb Co	Terapia combinada para el melanoma
JP2022505647A (ja)	2018-10-23	2022-01-14	ブリストル－マイヤーズスクイブカンパニー	腫瘍の処置方法
TWI844571B (zh)	2018-10-30	2024-06-11	丹麥商珍美寶股份有限公司	使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US20230053449A1 (en)	2018-10-31	2023-02-23	Novartis Ag	Dc-sign antibody drug conjugates
WO2020097409A2 (en)	2018-11-08	2020-05-14	Modernatx, Inc.	Use of mrna encoding ox40l to treat cancer in human patients
EP3876955A4 (en)	2018-11-09	2022-08-24	Pierian Biosciences, LLC	METHODS AND COMPOSITIONS FOR DETERMINING THE COMPOSITION OF A TUMOR MICROENVIRONMENT
CN112996814B (zh)	2018-11-14	2025-01-03	拜耳公司	用于治疗癌症的抗ceacam6和抗pd-1或抗pd-l1抗体的药物组合
CA3119341A1 (en)	2018-11-16	2020-05-22	Neoimmunetech, Inc.	Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US11274150B2 (en)	2018-11-16	2022-03-15	Bristol-Myers Squibb Company	Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
CN109452229B (zh) *	2018-11-19	2021-10-22	百奥赛图(北京)医药科技股份有限公司	狗源化pd-1基因改造动物模型的制备方法及应用
KR102885855B1 (ko)	2018-11-19	2025-11-14	바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드	항-pd-1 항체 및 이의 용도
WO2020106695A1 (en)	2018-11-19	2020-05-28	Ariagen, Inc.	Methods of treating cancer
EP3883955A1 (en)	2018-11-19	2021-09-29	Board of Regents, The University of Texas System	A modular, polycistronic vector for car and tcr transduction
WO2020104479A1 (en)	2018-11-20	2020-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
EP3883964A1 (en)	2018-11-20	2021-09-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Bispecific antibody targeting transferrin receptor 1 and soluble antigen
CA3121027A1 (en)	2018-11-28	2020-06-04	Board Of Regents, The University Of Texas System	Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en)	2018-11-29	2020-06-04	Board Of Regents, The University Of Texas System	Methods for ex vivo expansion of natural killer cells and use thereof
CA3121573A1 (en)	2018-12-03	2020-06-11	Agensys, Inc.	Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
CN113167802B (zh)	2018-12-04	2025-02-07	百时美施贵宝公司	通过多同位素体反应监测使用样品内校准曲线的分析方法
CA3119807A1 (en)	2018-12-04	2020-06-11	Sumitomo Dainippon Pharma Oncology, Inc.	Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
KR102195135B1 (ko) *	2018-12-07	2020-12-24	한국과학기술원	면역조절제의 스크리닝 방법
WO2020115261A1 (en)	2018-12-07	2020-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
KR20210102925A (ko)	2018-12-10	2021-08-20	블루버드 바이오, 인코포레이티드.	호밍 엔도뉴클레아제 변이체
US20220177860A1 (en) *	2018-12-10	2022-06-09	2Seventy Bio, Inc.	Pdcd-1 homing endonuclease variants
EP3894401A2 (en)	2018-12-11	2021-10-20	Theravance Biopharma R&D IP, LLC	Naphthyridine and quinoline derivatives useful as alk5 inhibitors
EP3666905A1 (en)	2018-12-11	2020-06-17	Sanofi	E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
WO2020120592A1 (en)	2018-12-12	2020-06-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating melanoma
WO2020127411A1 (en)	2018-12-19	2020-06-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
BR112021007968A2 (pt)	2018-12-19	2021-09-08	Bayer Aktiengesellschaft	Combinação farmacêutica de anticorpos anti-ceacam6 e tim3
CN113271945A (zh)	2018-12-20	2021-08-17	诺华股份有限公司	包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
WO2020127885A1 (en)	2018-12-21	2020-06-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions for treating cancers and resistant cancers
KR20210108422A (ko)	2018-12-21	2021-09-02	노파르티스 아게	IL-1β 결합 항체의 용도
IL282838B2 (en)	2018-12-21	2025-05-01	Valerio Therapeutics	Conjugated nucleic acid molecules and their uses
WO2020128637A1 (en)	2018-12-21	2020-06-25	Novartis Ag	Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3897854A2 (en)	2018-12-21	2021-10-27	Aim Immunotech Inc.	Compositions and methods for cancer therapy
US20220025036A1 (en)	2018-12-21	2022-01-27	Novartis Ag	Use of il-1beta binding antibodies
CN113227137A (zh)	2018-12-21	2021-08-06	诺华股份有限公司	IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
US11739156B2 (en)	2019-01-06	2023-08-29	The Broad Institute, Inc. Massachusetts Institute of Technology	Methods and compositions for overcoming immunosuppression
CN111423510B (zh)	2019-01-10	2024-02-06	迈威(上海)生物科技股份有限公司	重组抗人pd-1抗体及其应用
JP2022518399A (ja)	2019-01-14	2022-03-15	ジェネンテック，インコーポレイテッド	Ｐｄ－１軸結合アンタゴニスト及びｒｎａワクチンを用いてがんを処置する方法
WO2020150116A1 (en)	2019-01-14	2020-07-23	Innate Tumor Immunity, Inc.	Nlrp3 modulators
EP3911641A1 (en)	2019-01-14	2021-11-24	Innate Tumor Immunity, Inc.	Nlrp3 modulators
KR102815870B1 (ko)	2019-01-14	2025-05-30	인네이트 튜머 이뮤니티, 인코포레이티드	암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제
US12187706B2 (en)	2019-01-14	2025-01-07	Innate Tumor Immunity, Inc.	NLRP3 modulators
CN113507963A (zh)	2019-01-21	2021-10-15	赛诺菲	用于晚期实体瘤癌症的治疗性rna及抗pd1抗体
US20220107323A1 (en)	2019-01-30	2022-04-07	Inserm(Institut National De La Santé Et De La Recherche Médicale)	Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
WO2020161083A1 (en)	2019-02-04	2020-08-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for modulating blood-brain barrier
CA3127502A1 (en)	2019-02-12	2020-08-20	Sumitomo Dainippon Pharma Oncology, Inc.	Formulations comprising heterocyclic protein kinase inhibitors
JP2022519385A (ja)	2019-02-12	2022-03-23	ノバルティスアーゲー	Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ
EP3924520A1 (en)	2019-02-13	2021-12-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
JP7483732B2 (ja)	2019-02-15	2024-05-15	ノバルティスアーゲー	３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20220107320A1 (en)	2019-02-15	2022-04-07	Incelldx, Inc.	Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
EP3924055B1 (en)	2019-02-15	2024-04-03	Novartis AG	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020191079A1 (en)	2019-03-18	2020-09-24	The Broad Institute, Inc.	Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220184121A1 (en)	2019-03-18	2022-06-16	The Regents Of The University Of California	Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells
CN110297093B (zh) *	2019-03-18	2022-04-22	山西瑞豪生物科技有限公司	一种检测人免疫球蛋白g4的方法和试剂盒
US11793802B2 (en)	2019-03-20	2023-10-24	Sumitomo Pharma Oncology, Inc.	Treatment of acute myeloid leukemia (AML) with venetoclax failure
CA3133460A1 (en)	2019-03-22	2020-10-01	Sumitomo Dainippon Pharma Oncology, Inc.	Compositions comprising pkm2 modulators and methods of treatment using the same
JP2022526960A (ja)	2019-03-28	2022-05-27	ブリストル－マイヤーズスクイブカンパニー	腫瘍を処置する方法
EP3946625A1 (en)	2019-03-28	2022-02-09	Bristol-Myers Squibb Company	Methods of treating tumor
US20220175815A1 (en)	2019-04-03	2022-06-09	Orega Biotech	Combination therapies based on pd1 and il-17b inhibitors
CA3137027A1 (en)	2019-04-15	2020-10-22	Ariagen, Inc.	Chiral indole compounds and their use
WO2020214957A1 (en)	2019-04-19	2020-10-22	Tcrcure Biopharma Corp.	Anti-pd-1 antibodies and uses thereof
EP3725370A1 (en)	2019-04-19	2020-10-21	ImmunoBrain Checkpoint, Inc.	Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
TW202043291A (zh)	2019-04-19	2020-12-01	美商建南德克公司	抗mertk抗體及使用方法
KR102446655B1 (ko) *	2019-04-29	2022-09-23	연세대학교 산학협력단	면역항암 보조제
US20220220565A1 (en)	2019-04-30	2022-07-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
CN114144514B (zh)	2019-05-09	2025-11-25	富士胶片细胞动力公司	产生肝细胞的方法
US20230295087A1 (en)	2019-05-13	2023-09-21	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2020231713A1 (en)	2019-05-13	2020-11-19	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
KR20230031981A (ko)	2019-05-14	2023-03-07	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
US10945981B2 (en)	2019-05-17	2021-03-16	Cancer Prevention Pharmaceuticals, Inc.	Methods for treating familial adenomatous polyposis
WO2020239558A1 (en)	2019-05-24	2020-12-03	Pfizer Inc.	Combination therapies using cdk inhibitors
CN114174538A (zh)	2019-05-30	2022-03-11	百时美施贵宝公司	适合于免疫肿瘤学疗法的多肿瘤基因特征
EP3977132A1 (en)	2019-05-30	2022-04-06	Bristol-Myers Squibb Company	Cell localization signature and combination therapy
KR20220016155A (ko)	2019-05-30	2022-02-08	브리스톨-마이어스 스큅 컴퍼니	면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
CN114206355A (zh)	2019-06-03	2022-03-18	芝加哥大学	用靶向癌症的佐剂治疗癌症的方法和组合物
EP3976111A4 (en)	2019-06-03	2023-07-05	The University of Chicago	Methods and compositions for treating cancer with collagen binding drug carriers
WO2020249001A1 (zh)	2019-06-10	2020-12-17	百济神州瑞士有限责任公司	一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
US11246906B2 (en)	2019-06-11	2022-02-15	Alkermes Pharma Ireland Limited	Compositions and methods for subcutaneous administration of cancer immunotherapy
MA56533A (fr)	2019-06-18	2022-04-27	Janssen Sciences Ireland Unlimited Co	Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
JP2022536850A (ja)	2019-06-18	2022-08-19	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
CN112225809B (zh) *	2019-06-30	2023-09-05	福州创方医药科技有限公司	一种靶向pd-1的单克隆抗体及其应用
CN117447596A (zh) *	2019-06-30	2024-01-26	福州创方医药科技有限公司	一种靶向pd-1的单克隆抗体及其应用
WO2021003417A1 (en)	2019-07-03	2021-01-07	Sumitomo Dainippon Pharma Oncology, Inc.	Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
WO2021006199A1 (ja)	2019-07-05	2021-01-14	小野薬品工業株式会社	Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021026179A1 (en)	2019-08-06	2021-02-11	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7771749B2 (ja)	2019-08-08	2025-11-18	小野薬品工業株式会社	二重特異性タンパク質
WO2021030627A1 (en)	2019-08-13	2021-02-18	The General Hospital Corporation	Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en)	2019-08-16	2025-09-23	The Broad Institute, Inc.	Methods for predicting outcomes and treating colorectal cancer using a cell atlas
GB201912107D0 (en)	2019-08-22	2019-10-09	Amazentis Sa	Combination
WO2021042019A1 (en)	2019-08-30	2021-03-04	Agenus Inc.	Anti-cd96 antibodies and methods of use thereof
WO2021048292A1 (en)	2019-09-11	2021-03-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
US20220387404A1 (en) *	2019-09-11	2022-12-08	Beigene, Ltd.	Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
US12121565B2 (en)	2019-09-13	2024-10-22	Duke University	Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
US20220411388A1 (en)	2019-09-17	2022-12-29	Bial - R&D Investments, S.A.	Substituted imidazole carboxamides and their use in the treatment of medical disorders
AU2020351178A1 (en)	2019-09-17	2022-03-17	Bial-R&D Investments, S.A.	Substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
WO2021055627A1 (en)	2019-09-17	2021-03-25	Bial- Biotech Investments, Inc.	Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
BR112022004316A2 (pt)	2019-09-22	2022-06-21	Bristol Myers Squibb Co	Caracterização espacial quantitativa para terapia de antagonista lag-3
CA3152025A1 (en)	2019-09-24	2021-04-01	David BRIERE	Combination therapies
MX2022003357A (es)	2019-09-25	2022-05-03	Seagen Inc	Combinación de anticuerpo anti-cd30 conjugado con un farmaco, anti-pd-1 y quimioterapia para el tratamiento de cánceres hematopoyéticos.
AU2020353079A1 (en)	2019-09-25	2022-04-14	Bristol-Myers Squibb Company	Composite biomarker for cancer therapy
US20220354811A1 (en)	2019-10-03	2022-11-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for modulating macrophages polarization
US11981922B2 (en)	2019-10-03	2024-05-14	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en)	2019-10-03	2025-01-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en)	2019-10-07	2023-10-24	The Broad Institute, Inc.	Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
GB201914747D0 (en)	2019-10-11	2019-11-27	Ultrahuman Eight Ltd	PD1 and vegfr2 dual-binding agents
US12380963B2 (en)	2019-10-14	2025-08-05	The Medical College Of Wisconsin, Inc.	Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy
US20240301497A1 (en)	2019-10-17	2024-09-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing nasal intestinal type adenocarcinomas
MX2022004766A (es)	2019-10-21	2022-05-16	Novartis Ag	Terapias combinadas con venetoclax e inhibidores de tim-3.
TW202128191A (zh)	2019-10-21	2021-08-01	瑞士商諾華公司	Tim-3抑制劑及其用途
MX2022004942A (es)	2019-10-24	2022-07-27	Prometheus Biosciences Inc	Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
US20220409724A1 (en)	2019-10-29	2022-12-29	Eisai R&D Management Co., Ltd.	Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
US20240122938A1 (en)	2019-10-29	2024-04-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating uveal melanoma
WO2021087458A2 (en)	2019-11-02	2021-05-06	Board Of Regents, The University Of Texas System	Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
EP4055153A4 (en)	2019-11-04	2024-02-14	Duke University	TREATMENT OF PRIMARY AND METASTASIC CANCER
US20220390455A1 (en)	2019-11-05	2022-12-08	Bristol-Myers Squibb Company	M-protein assays and uses thereof
WO2021092221A1 (en)	2019-11-06	2021-05-14	Bristol-Myers Squibb Company	Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en)	2019-11-06	2021-05-14	Bristol-Myers Squibb Company	Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
KR20220093349A (ko)	2019-11-08	2022-07-05	브리스톨-마이어스 스큅 컴퍼니	흑색종에 대한 lag-3 길항제 요법
TWI895295B (zh)	2019-11-12	2025-09-01	美商方得生醫療公司	偵測編碼新生抗原之融合基因之方法
CN112794906B (zh) *	2019-11-13	2022-04-05	合肥瀚科迈博生物技术有限公司	抗4-1bb的单链抗体及其应用
CN114728905B (zh)	2019-11-13	2025-08-01	基因泰克公司	治疗性化合物及使用方法
EP4058465A1 (en)	2019-11-14	2022-09-21	Cohbar Inc.	Cxcr4 antagonist peptides
CN115151563A (zh) *	2019-11-21	2022-10-04	百济神州有限公司	使用抗ox40抗体与抗pd1或抗pdl1抗体组合治疗癌症的方法
JP2023502264A (ja)	2019-11-22	2023-01-23	スミトモファーマオンコロジー，インコーポレイテッド	固体用量医薬組成物
WO2021102468A1 (en)	2019-11-22	2021-05-27	Theravance Biopharma R&D Ip, Llc	Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
GB201917254D0 (en)	2019-11-27	2020-01-08	Adc Therapeutics Sa	Combination therapy
WO2021113644A1 (en)	2019-12-05	2021-06-10	Multivir Inc.	Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CA3164124A1 (en)	2019-12-09	2021-06-17	Seagen Inc.	Combination therapy with liv1-adc and pd-1 antagonist
EP4076508A1 (en)	2019-12-19	2022-10-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and vaccine compositions to treat cancers
MX2022006932A (es)	2019-12-19	2022-07-11	Bristol Myers Squibb Co	Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
CN113004408B (zh) *	2019-12-20	2022-07-01	广东菲鹏制药股份有限公司	抗人程序死亡因子-1单克隆抗体
TW202135859A (zh)	2019-12-20	2021-10-01	瑞士商諾華公司	組合療法
KR20220124718A (ko)	2020-01-07	2022-09-14	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	암 치료를 위한 개선된 인간 메틸 티오아데노신/아데노신 고갈 효소 변이체
US12492200B2 (en)	2020-01-10	2025-12-09	Birstol Myers-Squibb Company	NLRP3 modulators
EP4090770A1 (en)	2020-01-17	2022-11-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
BR112022012310A2 (pt)	2020-01-17	2022-09-06	Novartis Ag	Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
IL295093A (en)	2020-01-30	2022-09-01	Ona Therapeutics S L	Combination therapy for treatment of cancer and cancer metastasis
WO2021155149A1 (en)	2020-01-31	2021-08-05	Genentech, Inc.	Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
US20230072528A1 (en)	2020-02-05	2023-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
EP4100426A1 (en)	2020-02-06	2022-12-14	Bristol-Myers Squibb Company	Il-10 and uses thereof
EP4107173A1 (en)	2020-02-17	2022-12-28	Board of Regents, The University of Texas System	Methods for expansion of tumor infiltrating lymphocytes and use thereof
EP4110341A2 (en)	2020-02-28	2023-01-04	Novartis AG	A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
EP4110810A1 (en)	2020-02-28	2023-01-04	Orega Biotech	Combination therapies based on ctla4 and il-17b inhibitors
US20230113705A1 (en)	2020-02-28	2023-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2022074464A2 (en)	2020-03-05	2022-04-14	Neotx Therapeutics Ltd.	Methods and compositions for treating cancer with immune cells
AU2021232158A1 (en)	2020-03-06	2022-09-29	Ona Therapeutics, S.L.	Anti-CD36 antibodies and their use to treat cancer
WO2021178807A1 (en)	2020-03-06	2021-09-10	Celgene Quanticel Research, Inc.	Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
EP3878446A1 (en)	2020-03-09	2021-09-15	Universite De Geneve	Hsd11b1 inhibitors for use in immunotherapy and uses thereof
US20230119066A1 (en)	2020-03-23	2023-04-20	Bristol-Myers Squibb Company	Anti-ccr8 antibodies for treating cancer
CA3172449A1 (en)	2020-03-27	2021-09-30	Erik Hans MANTING	Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN115443269A (zh)	2020-03-31	2022-12-06	施万生物制药研发Ip有限责任公司	经取代的嘧啶和使用方法
WO2021214623A1 (en)	2020-04-21	2021-10-28	Novartis Ag	Dosing regimen for treating a disease modulated by csf-1r
US12159700B2 (en)	2020-04-22	2024-12-03	Iovance Biotherapeutics, Inc.	Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CN115515973B (zh)	2020-05-06	2025-12-12	高丽大学校产学协力团	增加pd-l1亲和度的pd-1变异体
KR102623161B1 (ko) *	2020-10-08	2024-01-09	고려대학교 산학협력단	Pd-l1 친화도가 증가된 pd-1 변이체
CA3178726A1 (en)	2020-05-21	2021-11-25	Gregory LIZEE	T cell receptors with vgll1 specificity and uses thereof
WO2021243207A1 (en)	2020-05-28	2021-12-02	Modernatx, Inc.	Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
WO2021247836A1 (en)	2020-06-03	2021-12-09	Board Of Regents, The University Of Texas System	Methods for targeting shp-2 to overcome resistance
TW202214623A (zh)	2020-06-10	2022-04-16	美商施萬生物製藥研發 Ip有限責任公司	結晶型alk5抑制劑及其用途
IL298999A (en)	2020-06-11	2023-02-01	Provention Bio Inc	Methods and compositions for the prevention of type 1 diabetes
TW202214857A (zh)	2020-06-19	2022-04-16	法商昂席歐公司	新型結合核酸分子及其用途
KR20230027056A (ko)	2020-06-23	2023-02-27	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
AU2021296917A1 (en)	2020-06-26	2023-02-02	Amgen Inc.	IL-10 muteins and fusion proteins thereof
CN116133679A (zh)	2020-06-30	2023-05-16	门德斯有限公司	白血病衍生细胞在卵巢癌疫苗中的用途
KR20230035576A (ko)	2020-07-07	2023-03-14	비온테크 에스이	Hpv 양성 암 치료용 rna
WO2022009157A1 (en)	2020-07-10	2022-01-13	Novartis Ag	Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en)	2020-07-24	2023-10-17	Genentech, Inc.	Therapeutic compounds and methods of use
WO2022023379A1 (en)	2020-07-28	2022-02-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for preventing and treating a cancer
US20230271940A1 (en)	2020-08-03	2023-08-31	Novartis Ag	Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022032228A1 (en)	2020-08-07	2022-02-10	The Broad Institute, Inc.	Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
MX2023002332A (es)	2020-08-28	2023-03-21	Bristol Myers Squibb Co	Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
WO2022043557A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
CA3190660A1 (en)	2020-08-31	2022-03-03	George C. Lee	Cell localization signature and immunotherapy
US20230338587A1 (en)	2020-08-31	2023-10-26	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
EP4208482A1 (en)	2020-09-02	2023-07-12	Pharmabcine Inc.	Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
US20220089738A1 (en)	2020-09-24	2022-03-24	Merck Sharp & Dohme Corp.	Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
CN112285224A (zh) *	2020-10-02	2021-01-29	朱吉安	一种抗pd-1单克隆抗体药物的质量标准检测方法
JP2023544410A (ja)	2020-10-05	2023-10-23	ブリストル－マイヤーズスクイブカンパニー	タンパク質を濃縮するための方法
US20230364127A1 (en)	2020-10-06	2023-11-16	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting stat6
WO2022086957A1 (en)	2020-10-20	2022-04-28	Genentech, Inc.	Peg-conjugated anti-mertk antibodies and methods of use
CA3196496A1 (en)	2020-10-23	2022-04-28	Laurence David TOMS	Lag-3 antagonist therapy for lung cancer
WO2022084531A1 (en)	2020-10-23	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating glioma
KR20230098279A (ko)	2020-10-28	2023-07-03	이케나 온콜로지, 인코포레이티드	Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합
WO2022093981A1 (en)	2020-10-28	2022-05-05	Genentech, Inc.	Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
IL302217A (en)	2020-11-04	2023-06-01	Genentech Inc	Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
IL302396A (en)	2020-11-04	2023-06-01	Genentech Inc	Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
JP7716473B2 (ja)	2020-11-04	2025-07-31	ジェネンテック，インコーポレイテッド	抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
US20240009241A1 (en)	2020-11-05	2024-01-11	Board Of Regents, The University Of Texas System	Engineered t cell receptors targeting egfr antigens and methods of use
IL302569A (en)	2020-11-06	2023-07-01	Novartis Ag	Cd19 binding molecules and uses thereof
CA3201499A1 (en)	2020-11-13	2022-05-19	Catamaran Bio, Inc.	Genetically modified natural killer cells and methods of use thereof
EP4244391A1 (en)	2020-11-16	2023-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating uveal melanoma
US20230416838A1 (en)	2020-11-16	2023-12-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating uveal melanoma
AU2021383611A1 (en)	2020-11-17	2023-06-29	Peter Maccallum Cancer Institute	Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
WO2022115611A1 (en)	2020-11-25	2022-06-02	Catamaran Bio, Inc.	Cellular therapeutics engineered with signal modulators and methods of use thereof
US20220168293A1 (en)	2020-12-02	2022-06-02	Pfizer Inc.	Time to resolution of axitinib-related adverse events
JP2023551906A (ja)	2020-12-02	2023-12-13	ジェネンテック，インコーポレイテッド	ネオアジュバントおよびアジュバント尿路上皮癌腫療法のための方法および組成物
WO2022120179A1 (en)	2020-12-03	2022-06-09	Bristol-Myers Squibb Company	Multi-tumor gene signatures and uses thereof
PH12023500013A1 (en)	2020-12-04	2024-03-11	Tidal Therapeutics Inc	Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
CA3196999A1 (en)	2020-12-28	2022-07-07	Masano HUANG	Methods of treating tumors
SMT202500208T1 (it)	2020-12-28	2025-07-22	Bristol Myers Squibb Co	Composizioni anticorpali e metodi per il loro uso
WO2022159492A1 (en)	2021-01-19	2022-07-28	William Marsh Rice University	Bone-specific delivery of polypeptides
CA3203705A1 (en)	2021-01-22	2022-07-28	Erik Hans MANTING	Methods of tumor vaccination
CA3210196A1 (en)	2021-01-29	2022-08-04	Board Of Regents, The University Of Texas System	Methods of treating cancer with kinase inhibitors
EP4284510A1 (en)	2021-01-29	2023-12-06	Novartis AG	Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
CA3206549A1 (en)	2021-01-29	2022-08-04	Frederick G. Vogt	Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
WO2022169921A1 (en)	2021-02-04	2022-08-11	Bristol-Myers Squibb Company	Benzofuran compounds as sting agonists
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
IL305795A (en) *	2021-03-10	2023-11-01	B G Negev Technologies & Applications Ltd At Ben Gurion Univ	Reporter cells expressing chimeric proteins for use in determining the presence and or activity of immune barrier molecules
WO2022190058A1 (en)	2021-03-12	2022-09-15	Dcprime B.V.	Methods of vaccination and use of cd47 blockade
EP4308118A1 (en)	2021-03-17	2024-01-24	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods and compositions for treating melanoma
WO2022195551A1 (en)	2021-03-18	2022-09-22	Novartis Ag	Biomarkers for cancer and methods of use thereof
TW202304506A (zh)	2021-03-25	2023-02-01	日商安斯泰來製藥公司	涉及抗claudin 18.2抗體的組合治療以治療癌症
JP2024514245A (ja)	2021-03-29	2024-03-29	ジュノーセラピューティクスインコーポレイテッド	チェックポイント阻害剤療法とｃａｒｔ細胞療法との組合せを用いた投薬および処置のための方法
EP4314068A1 (en)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022253474A1 (en)	2021-04-08	2023-11-16	Board Of Regents, The University Of Texas System	Compounds and methods for theranostic targeting of parp activity
CA3213079A1 (en)	2021-04-13	2022-10-20	Kristin Lynne ANDREWS	Amino-substituted heterocycles for treating cancers with egfr mutations
EP4322938A1 (en)	2021-04-14	2024-02-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	New method to improve nk cells cytotoxicity
EP4326903A1 (en)	2021-04-23	2024-02-28	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating cell senescence accumulation related disease
TW202243689A (zh)	2021-04-30	2022-11-16	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
WO2022232503A1 (en)	2021-04-30	2022-11-03	Genentech, Inc.	Therapeutic and diagnostic methods and compositions for cancer
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
EP4346887A1 (en)	2021-05-25	2024-04-10	Edelweiss Immune Inc	C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
WO2022251359A1 (en)	2021-05-26	2022-12-01	Theravance Biopharma R&D Ip, Llc	Bicyclic inhibitors of alk5 and methods of use
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
GB202107994D0 (en)	2021-06-04	2021-07-21	Kymab Ltd	Treatment of cancer
MX2023015206A (es)	2021-06-18	2024-03-25	Genzyme Corp	Formulaciones de anticuerpos anti-tgf-beta y su uso.
KR20240028452A (ko)	2021-07-02	2024-03-05	제넨테크, 인크.	암을 치료하기 위한 방법 및 조성물
AU2022312698A1 (en)	2021-07-13	2024-01-25	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023010094A2 (en)	2021-07-28	2023-02-02	Genentech, Inc.	Methods and compositions for treating cancer
AU2022317820A1 (en)	2021-07-28	2023-12-14	F. Hoffmann-La Roche Ag	Methods and compositions for treating cancer
EP4377344A1 (en)	2021-07-30	2024-06-05	Ona Therapeutics S.L.	Anti-cd36 antibodies and their use to treat cancer
CA3228262A1 (en)	2021-08-04	2023-02-09	The Regents Of The University Of Colorado, A Body Corporate	Lat activating chimeric antigen receptor t cells and methods of use thereof
MX2024002281A (es)	2021-08-23	2024-05-20	Immunitas Therapeutics Inc	Anticuerpos anti-cd161 y usos de los mismos.
IL310773A (en)	2021-09-02	2024-04-01	Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts	Anti-CECAM6 antibodies with reduced side effects
EP4398889A1 (en)	2021-09-10	2024-07-17	Leap Therapeutics, Inc.	Combination therapy
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
WO2023051926A1 (en)	2021-09-30	2023-04-06	BioNTech SE	Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
WO2023057882A1 (en)	2021-10-05	2023-04-13	Pfizer Inc.	Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023060136A1 (en)	2021-10-05	2023-04-13	Cytovia Therapeutics, Llc	Natural killer cells and methods of use thereof
JP2024536383A (ja)	2021-10-06	2024-10-04	ジェンマブエー／エス	併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
MX2024004365A (es)	2021-10-20	2024-04-25	Takeda Pharmaceuticals Co	Composiciones que actuan sobre el antigeno de maduracion de linfocitos b (bcma) y metodos de uso de las mismas.
US20240409934A1 (en)	2021-10-25	2024-12-12	Board Of Regents, The University Of Texas System	Foxo1-targeted therapy for the treatment of cancer
JP2024540106A (ja)	2021-10-28	2024-10-31	ライエル・イミュノファーマ・インコーポレイテッド	免疫細胞を培養するための方法
CN118176214A (zh)	2021-10-29	2024-06-11	百时美施贵宝公司	血液癌症的lag-3拮抗剂疗法
US20240426823A1 (en)	2021-11-03	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023079428A1 (en)	2021-11-03	2023-05-11	Pfizer Inc.	Combination therapies using tlr7/8 agonist
WO2023080900A1 (en)	2021-11-05	2023-05-11	Genentech, Inc.	Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en)	2021-11-09	2023-05-19	BioNTech SE	Tlr7 agonist and combinations for cancer treatment
CN118234519A (zh)	2021-11-12	2024-06-21	诺华股份有限公司	用于治疗肺癌的组合疗法
JP2024541508A (ja)	2021-11-24	2024-11-08	ジェネンテック，インコーポレイテッド	治療用インダゾール化合物およびがんの治療における使用方法
WO2023097194A2 (en)	2021-11-24	2023-06-01	Genentech, Inc.	Therapeutic compounds and methods of use
US20240294926A1 (en)	2021-12-16	2024-09-05	Valerio Therapeutics	New conjugated nucleic acid molecules and their uses
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
EP4452257A1 (en)	2021-12-21	2024-10-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
JP2025501238A (ja)	2021-12-30	2025-01-17	ネオイミューンテック，インコーポレイテッド	Ｉｌ－７タンパク質とｖｅｇｆアンタゴニストの併用による腫瘍の治療方法
WO2023133424A2 (en) *	2022-01-05	2023-07-13	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
MX2024008831A (es)	2022-01-26	2024-07-25	Bristol Myers Squibb Co	Terapia combinada para carcinoma hepatocelular.
JP2025504908A (ja)	2022-01-28	2025-02-19	アイオバンスバイオセラピューティクス，インコーポレイテッド	サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
WO2023164638A1 (en)	2022-02-25	2023-08-31	Bristol-Myers Squibb Company	Combination therapy for colorectal carcinoma
WO2023168404A1 (en)	2022-03-04	2023-09-07	Bristol-Myers Squibb Company	Methods of treating a tumor
CN119156403A (zh)	2022-03-08	2024-12-17	阿伦蒂斯治疗股份公司	抗紧密连接蛋白-1抗体增加t细胞可用性的用途
KR20240159621A (ko)	2022-03-18	2024-11-05	브리스톨-마이어스 스큅 컴퍼니	폴리펩티드를 단리하는 방법
AU2022450448A1 (en)	2022-04-01	2024-10-10	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023196988A1 (en)	2022-04-07	2023-10-12	Modernatx, Inc.	Methods of use of mrnas encoding il-12
WO2023196987A1 (en)	2022-04-07	2023-10-12	Bristol-Myers Squibb Company	Methods of treating tumor
EP4257609A1 (en)	2022-04-08	2023-10-11	iOmx Therapeutics AG	Combination therapies based on pd-1 inhibitors and sik3 inhibitors
CN119731651A (zh)	2022-04-08	2025-03-28	百时美施贵宝公司	三级淋巴结构的机器学习标识、分类和量化
KR20250004789A (ko) *	2022-04-14	2025-01-08	베이진 스위찰랜드 게엠베하	Pd-1 항체를 함유하는 안정한 고농도 아르기닌 제제 및 그의 사용 방법
EP4507704A1 (en)	2022-04-15	2025-02-19	Iovance Biotherapeutics, Inc.	Til expansion processes using specific cytokine combinations and/or akti treatment
EP4514382A1 (en)	2022-04-28	2025-03-05	Musc Foundation for Research Development	Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023214325A1 (en)	2022-05-05	2023-11-09	Novartis Ag	Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN114920830B (zh) *	2022-05-07	2023-05-16	北京大学	Vκ4-1-IgLC多肽及其用途
WO2023219613A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL316628A (en)	2022-05-12	2024-12-01	Genmab As	Binding agents capable of binding to CD27 in combination therapy
WO2023230554A1 (en)	2022-05-25	2023-11-30	Pfizer Inc.	Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023235847A1 (en)	2022-06-02	2023-12-07	Bristol-Myers Squibb Company	Antibody compositions and methods of use thereof
AU2023284422A1 (en)	2022-06-07	2024-12-19	Genentech, Inc.	Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
US11786531B1 (en)	2022-06-08	2023-10-17	Beigene Switzerland Gmbh	Methods of treating B-cell proliferative disorder
TW202423482A (zh)	2022-06-08	2024-06-16	美商泰德治療公司	可電離陽離子脂質和脂質奈米顆粒、及其合成方法和用途
TW202408571A (zh) *	2022-06-16	2024-03-01	英屬開曼群島商百濟神州有限公司	使用抗ｔｉｇｉｔ抗體治療淋巴瘤之方法
GB202209518D0 (en)	2022-06-29	2022-08-10	Snipr Biome Aps	Treating & preventing E coli infections
CA3261698A1 (en) *	2022-07-12	2024-01-18	Beigene Switzerland Gmbh	METHODS FOR PREPARING A HIGHLY CONCENTRATED PD1 ANTIBODY SOLUTION BY ULTRAFILTRATION/DIAFILTRATION (UF/DF)
AU2023305619A1 (en)	2022-07-13	2025-01-23	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20250039403A (ko) *	2022-07-15	2025-03-20	베이진 스위찰랜드 게엠베하	항-tigit 항체를 사용한 암 치료 방법
EP4558524A1 (en)	2022-07-19	2025-05-28	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4310197A1 (en)	2022-07-21	2024-01-24	Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda	Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
EP4561599A1 (en)	2022-07-27	2025-06-04	Astrazeneca AB	Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2024028794A1 (en)	2022-08-02	2024-02-08	Temple Therapeutics BV	Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024033399A1 (en)	2022-08-10	2024-02-15	Institut National de la Santé et de la Recherche Médicale	Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en)	2022-08-10	2024-02-15	Institut National de la Santé et de la Recherche Médicale	Sk2 inhibitor for the treatment of pancreatic cancer
WO2024041651A1 (en) *	2022-08-25	2024-02-29	Beigene, Ltd.	Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies
WO2024044675A1 (en)	2022-08-25	2024-02-29	Beigene, Ltd.	Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
WO2024041652A1 (en) *	2022-08-25	2024-02-29	Beigene, Ltd.	Methods of cancer treatment
CN120153254A (zh)	2022-09-01	2025-06-13	基因泰克公司	膀胱癌的治疗和诊断方法
WO2024056716A1 (en)	2022-09-14	2024-03-21	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024069009A1 (en)	2022-09-30	2024-04-04	Alentis Therapeutics Ag	Treatment of drug-resistant hepatocellular carcinoma
WO2024077166A1 (en)	2022-10-05	2024-04-11	Genentech, Inc.	Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en)	2022-10-05	2024-04-11	Genentech, Inc.	Methods and compositions for classifying and treating bladder cancer
WO2024086827A2 (en)	2022-10-20	2024-04-25	Repertoire Immune Medicines, Inc.	Cd8 t cell targeted il2
EP4605000A1 (en)	2022-10-21	2025-08-27	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of osteoarthritis
EP4609201A1 (en)	2022-10-25	2025-09-03	Genentech, Inc.	Therapeutic and diagnostic methods for multiple myeloma
KR20250089492A (ko)	2022-11-07	2025-06-18	네오이뮨텍, 인코퍼레이티드	비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
JP2025539816A (ja)	2022-11-21	2025-12-09	アイオバンスバイオセラピューティクス，インコーポレイテッド	腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
EP4622677A1 (en)	2022-11-24	2025-10-01	BeiGene Switzerland GmbH	Anti-cea antibody drug conjugates and methods of use
EP4626552A1 (en)	2022-12-01	2025-10-08	MedImmune Limited	Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
AU2023401158A1 (en)	2022-12-01	2025-05-29	BioNTech SE	Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024124044A1 (en)	2022-12-07	2024-06-13	The Brigham And Women’S Hospital, Inc.	Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
CN120418289A (zh)	2022-12-14	2025-08-01	安斯泰来制药欧洲有限公司	结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
EP4637807A2 (en)	2022-12-20	2025-10-29	Genentech Inc.	Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024137776A1 (en)	2022-12-21	2024-06-27	Bristol-Myers Squibb Company	Combination therapy for lung cancer
IL321948A (en)	2023-01-06	2025-09-01	Lassen Therapeutics Inc	Anti-IL-18 BP antibodies
WO2024148241A1 (en)	2023-01-06	2024-07-11	Lassen Therapeutics 1, Inc.	Anti-il-18bp antibodies
WO2024150177A1 (en)	2023-01-11	2024-07-18	Advesya	Treatment methods for solid tumors
WO2024151885A1 (en)	2023-01-13	2024-07-18	Iovance Biotherapeutics, Inc.	Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
IL322127A (en)	2023-01-19	2025-09-01	Beone Medicines I Gmbh	Anti-cmet antibodies and methods of use
CN120813375A (zh)	2023-01-30	2025-10-17	凯玛布有限公司	抗体
TW202432179A (zh) *	2023-02-08	2024-08-16	瑞士商百濟神州瑞士有限責任公司	用於高度濃縮的ｐｄ１抗體溶液的超濾／滲濾方法
CN120813377A (zh)	2023-02-23	2025-10-17	感应检查疗法公司	Btn3a活化抗体和免疫检查点抑制剂的组合
CN120813609A (zh)	2023-03-03	2025-10-17	广州百济神州生物制药有限公司	Muc1和cd16a抗体及使用方法
AR132043A1 (es)	2023-03-03	2025-05-21	Beigene Switzerland Gmbh	Anticuerpos muc1 y métodos de uso
WO2024184812A1 (en)	2023-03-06	2024-09-12	Beigene Switzerland Gmbh	Anti-cldn6 antibodies and methods of use
AR132062A1 (es)	2023-03-06	2025-05-21	Beigene Switzerland Gmbh	Anticuerpos multiespecíficos anti-cd3 y métodos de uso
TW202436353A (zh)	2023-03-06	2024-09-16	瑞士商百濟神州瑞士有限責任公司	抗ｃｌｄｎ６與抗ｃｄ３多重特異性抗體以及使用方法
WO2024196952A1 (en)	2023-03-20	2024-09-26	Bristol-Myers Squibb Company	Tumor subtype assessment for cancer therapy
WO2024200571A1 (en)	2023-03-28	2024-10-03	Institut National de la Santé et de la Recherche Médicale	Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024209072A1 (en)	2023-04-06	2024-10-10	Genmab A/S	Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2024216028A1 (en)	2023-04-12	2024-10-17	Agenus Inc.	Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
US20240368283A1 (en) *	2023-04-26	2024-11-07	Seismic Therapeutic, Inc.	Molecules for modulating the immune system and uses thereof
WO2024228167A1 (en)	2023-05-03	2024-11-07	Iox Therapeutics Inc.	Inkt cell modulator liposomal compositions and methods of use
WO2024233341A1 (en)	2023-05-05	2024-11-14	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024268933A1 (en)	2023-05-10	2025-11-20	Chugai Seiyaku Kabushiki Kaisha	Methods and compositions for treating cancer
WO2024231384A1 (en)	2023-05-10	2024-11-14	Institut National de la Santé et de la Recherche Médicale	Compositions for treating senescence related disease
TW202509071A (zh)	2023-05-12	2025-03-01	丹麥商珍美寶股份有限公司	能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2024236048A1 (en)	2023-05-16	2024-11-21	Nh Theraguix	Combination therapy for treating tumors with radiotherapy
TW202446419A (zh) *	2023-05-25	2024-12-01	瑞士商百濟神州瑞士有限責任公司	使用抗ｏｘ４０抗體與抗ｐｄ１抗體之組合的癌症治療方法
WO2024245951A1 (en)	2023-05-26	2024-12-05	Institut National de la Santé et de la Recherche Médicale	Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024256635A1 (en)	2023-06-15	2024-12-19	Institut National de la Santé et de la Recherche Médicale	Dpm1 inhibitor for treating cancer
WO2024263904A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2024261239A1 (en)	2023-06-23	2024-12-26	Imcheck Therapeutics	Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2024263195A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2025006811A1 (en)	2023-06-27	2025-01-02	Lyell Immunopharma, Inc.	Methods for culturing immune cells
WO2025024257A1 (en)	2023-07-21	2025-01-30	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
WO2025034883A1 (en)	2023-08-08	2025-02-13	Quanta Therapeutics, Inc.	Combination therapies with kras modulators
WO2025038763A1 (en)	2023-08-15	2025-02-20	Bristol-Myers Squibb Company	Ceramic hydroxyapatite chromatography flow through method
TW202515614A (zh)	2023-08-25	2025-04-16	美商建南德克公司	治療非小細胞肺癌之方法及組成物
TW202511497A (zh)	2023-09-01	2025-03-16	瑞士商百濟神州瑞士有限責任公司	免疫相關基因表現特徵及其相關方法
WO2025050009A2 (en)	2023-09-01	2025-03-06	Children's Hospital Medical Center	Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
WO2025056180A1 (en)	2023-09-15	2025-03-20	BioNTech SE	Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma
WO2025078632A1 (en)	2023-10-12	2025-04-17	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from cancer
TW202515903A (zh)	2023-10-12	2025-04-16	瑞士商百濟神州瑞士有限責任公司	手術前後基於抗ｐｄ－１之治療
WO2025085404A1 (en)	2023-10-16	2025-04-24	Genentech, Inc.	Diagnostic and therapeutic methods for treating lung cancer
WO2025106905A1 (en)	2023-11-17	2025-05-22	Quanta Therapeutics, Inc.	Combination therapies with a kras modulator and an immunomodulator inhibitor
WO2025114541A1 (en)	2023-11-30	2025-06-05	Genmab A/S	Antibodies capable of binding to ox40 in combination therapy
WO2025121445A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025132479A1 (en)	2023-12-18	2025-06-26	Institut National de la Santé et de la Recherche Médicale	Flt3 inhibitor for modulating macrophages polarization
WO2025132770A1 (en)	2023-12-22	2025-06-26	Institut National de la Santé et de la Recherche Médicale	Affitins for the treatment of cancer
US20250215087A1 (en)	2023-12-29	2025-07-03	Bristol-Myers Squibb Company	Combination therapy of kras inhibitor and treg depleting agent
US20250222125A1 (en)	2024-01-05	2025-07-10	Beigene, Ltd.	Anti-FGFR2b Antibodies, Conjugates and Methods of Use
WO2025155607A1 (en)	2024-01-16	2025-07-24	Genentech, Inc.	Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
WO2025174825A2 (en)	2024-02-12	2025-08-21	Aera Therapeutics, Inc.	Delivery compositions
WO2025174933A1 (en)	2024-02-14	2025-08-21	Genentech, Inc.	Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
US20250269052A1 (en)	2024-02-27	2025-08-28	Bristol-Myers Squibb Company	Anti-ceacam5 antibody drug conjugates
WO2025184208A1 (en)	2024-02-27	2025-09-04	Bristol-Myers Squibb Company	Anti-ceacam5 antibodies and uses thereof
WO2025210123A1 (en)	2024-04-03	2025-10-09	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for treating cancers
WO2025219330A1 (en)	2024-04-15	2025-10-23	Institut National de la Santé et de la Recherche Médicale	Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025228998A1 (en)	2024-04-30	2025-11-06	Institut National de la Santé et de la Recherche Médicale	Use of hdac4 inhibitors for the treatment of melanoma
WO2025232879A1 (en)	2024-05-10	2025-11-13	Cytocares (Shanghai) Inc.	Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025245489A1 (en)	2024-05-24	2025-11-27	Bristol-Myers Squibb Company	Treatment of tumors in subjects having fgl-1 positive samples
WO2025247829A1 (en)	2024-05-27	2025-12-04	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for treating prostate cancer
WO2025248505A1 (en)	2024-05-31	2025-12-04	Wayne State University	Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792533A (fr)	1971-12-09	1973-06-08	Int Chem & Nuclear Corp	Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
DE3883899T3 (de)	1987-03-18	1999-04-22	Sb2, Inc., Danville, Calif.	Geänderte antikörper.
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5994514A (en)	1991-08-14	1999-11-30	Genentech, Inc.	Immunoglobulin variants
EP0640094A1 (en)	1992-04-24	1995-03-01	The Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994029351A2 (en)	1993-06-16	1994-12-22	Celltech Limited	Antibodies
JPH07291996A (ja)	1994-03-01	1995-11-07	Yuu Honshiyo	ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
JP2778921B2 (ja)	1994-11-18	1998-07-23	三共株式会社	イミダゾピラゾール誘導体
US6528624B1 (en)	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
KR101077001B1 (ko)	1999-01-15	2011-10-26	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
IL148021A0 (en)	1999-08-23	2002-09-12	Dana Farber Cancer Inst Inc	Novel b7-4 molecules and uses therefor
DK1210428T3 (en)	1999-08-23	2015-06-15	Dana Farber Cancer Inst Inc	PD-1, a receptor for B7-4 AND USE THEREOF
ES2222919T3 (es)	1999-08-27	2005-02-16	Abbott Laboratories	Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2.
DE60004685T2 (de)	1999-09-17	2004-07-29	Abbott Gmbh & Co. Kg	Pyrazolopyrimidine als arzneimittel
IL151873A0 (en) *	2000-03-24	2003-04-10	Micromet Ag	Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CA2399940A1 (en)	2000-04-13	2001-10-25	The Rockefeller University	Enhancement of antibody-mediated immune responses
US20020094989A1 (en)	2000-10-11	2002-07-18	Hale Jeffrey J.	Pyrrolidine modulators of CCR5 chemokine receptor activity
EP1334659B1 (en)	2000-11-15	2012-01-11	Ono Pharmaceutical Co., Ltd.	Pd-1-lacking mouse and use thereof
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
DK1347971T3 (da)	2000-12-21	2006-05-15	Bristol Myers Squibb Co	Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
RU2003129528A (ru)	2001-03-07	2005-04-10	Мерк Патент ГмбХ (DE)	Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002072576A1 (en)	2001-03-09	2002-09-19	Pfizer Products Inc.	Benzimidazole anti-inflammatory compounds
AR036993A1 (es)	2001-04-02	2004-10-20	Wyeth Corp	Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
JPWO2003004497A1 (ja)	2001-07-05	2004-10-28	住友製薬株式会社	新規複素環化合物
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US8093357B2 (en)	2002-03-01	2012-01-10	Xencor, Inc.	Optimized Fc variants and methods for their generation
EP1537878B1 (en)	2002-07-03	2010-09-22	Ono Pharmaceutical Co., Ltd.	Immunopotentiating compositions
CN1771231B (zh)	2002-08-26	2011-05-25	武田药品工业株式会社	钙受体调节性化合物及其用途
AU2003265585B2 (en)	2002-08-26	2008-07-03	Takeda Pharmaceutical Company Limited	Calcium receptor modulating compound and use thereof
US7608429B2 (en)	2002-10-31	2009-10-27	Genentech, Inc.	Methods and compositions for increasing antibody production
WO2004056875A1 (en)	2002-12-23	2004-07-08	Wyeth	Antibodies against pd-1 and uses therefor
CA2512729C (en)	2003-01-09	2014-09-16	Macrogenics, Inc.	Identification and engineering of antibodies with variant fc regions and methods of using same
US7960512B2 (en) *	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1591527B1 (en)	2003-01-23	2015-08-26	Ono Pharmaceutical Co., Ltd.	Substance specific to human pd-1
US8084582B2 (en)	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
US20060183746A1 (en)	2003-06-04	2006-08-17	Currie Kevin S	Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005014599A1 (en)	2003-06-04	2005-02-17	Cellular Genomics, Inc.	Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en)	2003-06-30	2005-01-20	Cellular Genomics, Inc.	Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
MXPA06001098A (es)	2003-07-29	2006-04-24	Irm Llc	Compuestos y composiciones utiles como inhibidores de proteina cinasa.
WO2005018572A2 (en)	2003-08-22	2005-03-03	Biogen Idec Ma Inc.	Improved antibodies having altered effector function and methods for making the same
US20060134105A1 (en) *	2004-10-21	2006-06-22	Xencor, Inc.	IgG immunoglobulin variants with optimized effector function
WO2005047290A2 (en)	2003-11-11	2005-05-26	Cellular Genomics Inc.	Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
WO2005077981A2 (en)	2003-12-22	2005-08-25	Xencor, Inc.	Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
GB0400440D0 (en)	2004-01-09	2004-02-11	Isis Innovation	Receptor modulators
JP4958555B2 (ja)	2004-09-22	2012-06-20	協和発酵キリン株式会社	安定化されたヒトＩｇＧ４抗体
SG159549A1 (en)	2004-11-10	2010-03-30	Cgi Pharmaceuticals Inc	Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
RU2423351C2 (ru)	2004-12-16	2011-07-10	Вертекс Фармасьютикалз Инкорпорейтед	Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
TW200639163A (en)	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
BRPI0608252A2 (pt)	2005-03-10	2010-04-06	Cgi Pharmaceuticals Inc	entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
EP2418278A3 (en) *	2005-05-09	2012-07-04	Ono Pharmaceutical Co., Ltd.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907000T4 (da) *	2005-06-08	2020-03-30	The President And Fellows Of Harvard College	Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
KR101607288B1 (ko)	2005-07-01	2016-04-05	이. 알. 스퀴부 앤드 선즈, 엘.엘.씨.	예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1919906B1 (en)	2005-08-29	2011-10-12	Vertex Pharmaceuticals Incorporated	3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
JP2009507792A (ja)	2005-08-29	2009-02-26	バーテックスファーマシューティカルズインコーポレイテッド	非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
WO2007026720A1 (ja)	2005-08-31	2007-03-08	Taisho Pharmaceutical Co., Ltd.	縮環ピラゾール誘導体
BRPI0617100A2 (pt)	2005-09-01	2011-07-12	Astellas Pharma Inc	composto derivado de piridazinona, composição farmacêutica, método para previnir ou tratar uma doença e uso de um composto derivado de piridazinona
BRPI0619514A2 (pt)	2005-12-08	2011-10-04	Millennium Pharm Inc	compostos bicìclicos com atividade inibidora cinase, composição farmacêutica contendo os mesmos e uso de ditos compostos
CN101421269A (zh)	2006-01-13	2009-04-29	环状药物公司	酪氨酸激酶抑制剂及其用途
PL2004688T5 (pl) *	2006-03-23	2014-09-30	Bioarctic Neuroscience Ab	Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
WO2007136572A2 (en)	2006-05-15	2007-11-29	Merck & Co., Inc.	Antidiabetic bicyclic compounds
US8604031B2 (en)	2006-05-18	2013-12-10	Mannkind Corporation	Intracellular kinase inhibitors
TWI398252B (zh)	2006-05-26	2013-06-11	Novartis Ag	吡咯并嘧啶化合物及其用途
CN101104640A (zh)	2006-07-10	2008-01-16	苏州大学	抗人pd-l1单克隆抗体制备及应用
AR063946A1 (es)	2006-09-11	2009-03-04	Cgi Pharmaceuticals Inc	Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063706A1 (es)	2006-09-11	2009-02-11	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PE20081370A1 (es)	2006-09-11	2008-11-28	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
JP2010502751A (ja)	2006-09-11	2010-01-28	シージーアイファーマシューティカルズ，インコーポレイティド	キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
PT2201840E (pt)	2006-09-22	2012-02-14	Pharmacyclics Inc	Inibidores da tirosina quinase de bruton
AU2007308045A1 (en)	2006-10-06	2008-04-17	Irm Llc	Protein kinase inhibitors and methods for using thereof
EP2089391B1 (en)	2006-11-03	2013-01-16	Pharmacyclics, Inc.	Bruton's tyrosine kinase activity probe and method of using
EP2125819B1 (en)	2007-03-21	2014-10-22	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
JP6071165B2 (ja) *	2007-05-31	2017-02-01	ゲンマブエー／エス	安定なＩｇＧ４抗体
EP2535354B1 (en)	2007-06-18	2017-01-11	Merck Sharp & Dohme B.V.	Antibodies to human programmed death receptor pd-1
EP2195347A1 (en)	2007-08-17	2010-06-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating and diagnosing hematologic malignancies
CL2008002793A1 (es)	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
JO3076B1 (ar) *	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
CA2702674C (en)	2007-10-19	2016-05-03	Avila Therapeutics, Inc.	Heteroaryl compounds and uses thereof
US7989465B2 (en)	2007-10-19	2011-08-02	Avila Therapeutics, Inc.	4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2701275C (en)	2007-10-23	2016-06-21	F. Hoffmann-La Roche Ag	Kinase inhibitors
ES2462642T3 (es)	2007-12-14	2014-05-26	F. Hoffmann-La Roche Ag	Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
CA2710462C (en)	2008-02-05	2015-11-24	F. Hoffmann-La Roche Ag	Pyridinones and pyridazinones
CN101952454B (zh) *	2008-02-08	2014-06-04	米迪缪尼有限公司	具有减弱的Fc配体亲和性的抗IFNAR1抗体
US8168757B2 (en)	2008-03-12	2012-05-01	Merck Sharp & Dohme Corp.	PD-1 binding proteins
AU2009244291B2 (en)	2008-05-06	2014-02-13	Genentech, Inc.	Substituted amides, method of making, and use as Btk inhibitors
TWI458721B (zh)	2008-06-27	2014-11-01	Celgene Avilomics Res Inc	雜芳基化合物及其用途
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
JP5490789B2 (ja)	2008-07-02	2014-05-14	エフ．ホフマン−ラロシュアーゲー	キナーゼ阻害剤としての新規なフェニルピラジノン
ES2552681T3 (es)	2008-07-15	2015-12-01	F. Hoffmann-La Roche Ag	Nuevas fenil-imidazopiridinas y piridazinas
AU2009270856B2 (en)	2008-07-16	2013-07-25	Pharmacyclics Llc	Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
EP2307418B1 (en)	2008-07-18	2014-03-12	F.Hoffmann-La Roche Ag	Novel phenylimidazopyrazines
JP2011529073A (ja)	2008-07-24	2011-12-01	ブリストル−マイヤーズスクイブカンパニー	キナーゼ調節因子として有用な縮合ヘテロ環化合物
US20110159023A1 (en)	2008-08-25	2011-06-30	Solomon Langermann	Pd-1 antagonists and methods for treating infectious disease
CN102405284B (zh)	2008-09-05	2016-01-20	新基阿维罗米克斯研究公司	设计不可逆抑制剂的算法
WO2010029435A1 (en)	2008-09-12	2010-03-18	Isis Innovation Limited	Pd-1 specific antibodies and uses thereof
CA2736816C (en)	2008-09-12	2018-05-22	Isis Innovation Limited	Pd-1 specific antibodies and uses thereof
HUE030807T2 (en) *	2008-09-26	2017-05-29	Dana Farber Cancer Inst Inc	Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
KR101050829B1 (ko)	2008-10-02	2011-07-20	서울대학교산학협력단	항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP2348860B1 (en)	2008-10-31	2015-05-27	Genentech, Inc.	Pyrazolopyrimidine jak inhibitor compounds and methods
US20120028981A1 (en)	2008-11-05	2012-02-02	Principia Biopharma Inc.	Kinase Knockdown Via Electrophilically Enhanced Inhibitors
WO2010056875A1 (en)	2008-11-12	2010-05-20	Cgi Pharmaceuticals, Inc.	Pyridazinones and their use as btk inhibitors
JP5520961B2 (ja) *	2008-11-28	2014-06-11	エモリーユニバーシティ	感染症および腫瘍を処置するための方法
US8426428B2 (en)	2008-12-05	2013-04-23	Principia Biopharma, Inc.	EGFR kinase knockdown via electrophilically enhanced inhibitors
TWI729512B (zh) *	2008-12-09	2021-06-01	美商建南德克公司	抗pd-l1抗體及其於增進t細胞功能之用途
WO2010068788A1 (en)	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Heterocyclic amides as btk inhibitors
WO2010068806A1 (en)	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010068810A2 (en)	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
SG171815A1 (en)	2008-12-19	2011-07-28	Bristol Myers Squibb Co	Carbazole carboxamide compounds useful as kinase inhibitors
US20100197924A1 (en)	2008-12-22	2010-08-05	Millennium Pharmaceuticals, Inc.	Preparation of aminotetralin compounds
EP2379559B1 (en)	2009-01-06	2017-10-25	Dana-Farber Cancer Institute, Inc.	Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP3192811A1 (en) *	2009-02-09	2017-07-19	Université d'Aix-Marseille	Pd-1 antibodies and pd-l1 antibodies and uses thereof
US8299077B2 (en)	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
ES2513915T3 (es)	2009-04-24	2014-10-27	F. Hoffmann-La Roche Ag	Inhibidores de la tirosina quinasa de Bruton
EP2424368B1 (en)	2009-04-29	2014-12-31	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
ES2444777T3 (es)	2009-06-12	2014-02-26	Bristol-Myers Squibb Company	Compuestos de nicotinamida útiles como moduladores de quinasas
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2789615B1 (en)	2009-08-11	2017-05-03	Bristol-Myers Squibb Company	Azaindazoles as Btk kinase modulators and use thereof
US9493578B2 (en) *	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
PL2473049T3 (pl)	2009-09-04	2019-07-31	Biogen Ma Inc.	Inhibitory kinazy tyrozynowej brutona
US9029359B2 (en)	2009-09-04	2015-05-12	Biogen Idec Ma, Inc.	Heteroaryl Btk inhibitors
US7741330B1 (en)	2009-10-12	2010-06-22	Pharmacyclics, Inc.	Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011056644A2 (en) *	2009-10-28	2011-05-12	Centocor Ortho Biotech Inc.	Anti-glp-1r antibodies and their uses
SI2506871T1 (sl) *	2009-11-30	2016-12-30	Janssen Biotech, Inc.	Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
US10053513B2 (en) *	2009-11-30	2018-08-21	Janssen Biotech, Inc.	Antibody Fc mutants with ablated effector functions
US8329867B2 (en) *	2010-02-19	2012-12-11	Xencor, Inc.	CTLA4-Ig immunoadhesins
JP2013523098A (ja)	2010-03-29	2013-06-17	ザイムワークス，インコーポレイテッド	強化又は抑制されたエフェクター機能を有する抗体
ES2573716T3 (es)	2010-05-07	2016-06-09	Gilead Connecticut, Inc.	Compuestos de piridona y aza-piridona y métodos de utilización
MY169745A (en)	2010-05-31	2019-05-14	Ono Pharmaceutical Co	Purinone derivative
EA201890869A3 (ru)	2010-06-03	2019-03-29	Фармасайкликс, Инк.	Применение ингибиторов тирозинкиназы брутона (btk)
EP2582668B1 (en)	2010-06-16	2016-01-13	Bristol-Myers Squibb Company	Carboline carboxamide compounds useful as kinase inhibitors
LT2585470T (lt)	2010-06-23	2017-04-10	Hanmi Science Co., Ltd.	Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui
US20120053189A1 (en)	2010-06-28	2012-03-01	Pharmacyclics, Inc.	Btk inhibitors for the treatment of immune mediated conditions
US20120100166A1 (en) *	2010-07-15	2012-04-26	Zyngenia, Inc.	Ang-2 Binding Complexes and Uses Thereof
RU2013109393A (ru)	2010-08-10	2014-09-20	Сэлджин Авиаломикс Ресеарч, Инк.	Безилатная соль ингибитора втк
AR082590A1 (es)	2010-08-12	2012-12-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
CN103189369B (zh)	2010-09-01	2016-08-24	吉利德康涅狄格有限公司	吡啶酮/吡嗪酮、其制备方法及使用方法
EP2611798B1 (en)	2010-09-01	2015-04-08	Gilead Connecticut, Inc.	Pyridazinones, method of making, and method of use thereof
BR112013016235B1 (pt) *	2010-12-22	2020-03-31	Cephalon Australia Pty Ltd	Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
HUE041335T2 (hu)	2011-03-29	2019-05-28	Roche Glycart Ag	Antitest FC-variánsok
KR102031020B1 (ko) *	2011-03-31	2019-10-14	머크 샤프 앤드 돔 코포레이션	인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
WO2012135801A1 (en)	2011-04-01	2012-10-04	University Of Utah Research Foundation	Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CA2760174A1 (en)	2011-12-01	2013-06-01	Pharmascience Inc.	Protein kinase inhibitors and uses thereof
DK2699264T3 (en) *	2011-04-20	2018-06-25	Medimmune Llc	ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
US20140038989A1 (en)	2011-04-20	2014-02-06	Glaxo Group Limited	Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
BR112013029620A2 (pt)	2011-05-17	2016-09-06	Hoffmann La Roche	inibidores de tirosina quinase de bruton
US20140107151A1 (en)	2011-05-17	2014-04-17	Principia Biophama Inc.	Tyrosine kinase inhibitors
PL2710005T3 (pl)	2011-05-17	2017-07-31	Principia Biopharma Inc.	Inhibitory kinazy tyrozynowej
US9376438B2 (en)	2011-05-17	2016-06-28	Principia Biopharma, Inc.	Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
DK3424953T3 (en) *	2011-06-06	2020-11-02	Novo Nordisk As	Terapeutiske antistoffer
SG10201604682VA (en)	2011-06-10	2016-07-28	Merck Patent Gmbh	Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
CN103747803B (zh)	2011-06-22	2016-10-12	国家医疗保健研究所	抗axl抗体及其用途
ES2548414T3 (es)	2011-07-08	2015-10-16	Novartis Ag	Novedosos derivados de pirrolo pirimidina
BR122022000334B1 (pt) *	2011-08-01	2023-03-21	Genentech, Inc	Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
KR101981873B1 (ko)	2011-11-28	2019-05-23	메르크 파텐트 게엠베하	항-ｐｄ-ｌ1 항체 및 그의 용도
CN113527469A (zh)	2012-02-09	2021-10-22	中外制药株式会社	抗体的Fc区变异体
AU2013256802A1 (en)	2012-04-30	2014-12-11	Medimmune, Llc	Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
KR102702287B1 (ko)	2012-05-15	2024-09-04	브리스톨-마이어스 스큅 컴퍼니	Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
KR102410078B1 (ko)	2012-05-31	2022-06-22	소렌토 쎄라퓨틱스, 인코포레이티드	Pd-l1에 결합하는 항원 결합 단백질
JP2015526409A (ja) *	2012-07-03	2015-09-10	ヤンセン・サイエンシズ・アイルランド・ユーシー	Ｃ−末端及び中心エピトープａ−ベータ抗体
WO2014055897A2 (en)	2012-10-04	2014-04-10	Dana-Farber Cancer Institute, Inc.	Human monoclonal anti-pd-l1 antibodies and methods of use
US20140377269A1 (en) *	2012-12-19	2014-12-25	Adimab, Llc	Multivalent antibody analogs, and methods of their preparation and use
AR093984A1 (es)	2012-12-21	2015-07-01	Merck Sharp & Dohme	Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
TWI682941B (zh)	2013-02-01	2020-01-21	美商再生元醫藥公司	含嵌合恆定區之抗體
SMT201800435T1 (it) *	2013-02-20	2018-09-13	Regeneron Pharma	Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
MX364591B (es) *	2013-03-15	2019-05-02	Regeneron Pharma	Antagonistas de il-33 y usos de estos.
BR112015025260B1 (pt)	2013-04-25	2021-11-03	Beigene, Ltd	Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
HK1221964A1 (zh) *	2013-05-31	2017-06-16	Sorrento Therapeutics, Inc.	与pd-1结合的抗原结合蛋白
RS63571B9 (sr)	2013-09-13	2023-02-28	Beigene Switzerland Gmbh	Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
TWI660739B (zh)	2013-10-25	2019-06-01	製藥公司	使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
US10544225B2 (en)	2014-07-03	2020-01-28	Beigene, Ltd.	Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
TW201607930A (zh)	2014-07-18	2016-03-01	百濟神州有限公司	作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
US20170239351A1 (en)	2014-08-11	2017-08-24	Acerta Pharma B.V.	Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
CA2958139A1 (en)	2014-08-14	2016-02-18	Assia Chemical Industries Ltd.	Solid state forms of ibrutinib
TW201625304A (zh)	2014-10-24	2016-07-16	美國禮來大藥廠	泌尿上皮癌之療法
WO2016087994A1 (en)	2014-12-05	2016-06-09	Acerta Pharma B.V.	Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
CA2970723C (en)	2014-12-18	2023-09-05	Principia Biopharma Inc.	Treatment of pemphigus
HUE061809T2 (hu)	2014-12-24	2023-08-28	Principia Biopharma Inc	Készítmények csípõbél-éhbél szakaszba történõ hatóanyag beadáshoz
US9139653B1 (en) *	2015-04-30	2015-09-22	Kymab Limited	Anti-human OX40L antibodies and methods of treatment
JP7144935B2 (ja)	2015-05-29	2022-09-30	ジェネンテック，インコーポレイテッド	癌のための治療方法及び診断方法
WO2017024465A1 (en)	2015-08-10	2017-02-16	Innovent Biologics (Suzhou) Co., Ltd.	Pd-1 antibodies
US20190022092A1 (en)	2015-09-15	2019-01-24	Acerta Pharma B.V.	Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
JP2018530550A (ja)	2015-10-01	2018-10-18	ギリアドサイエンシズ，インコーポレイテッド	癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
WO2018007885A1 (en) *	2016-07-05	2018-01-11	Beigene, Ltd.	COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
JP7402685B2 (ja)	2016-08-16	2023-12-21	ベイジーンスウィッツァーランドゲーエムベーハー	（ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
AU2017313085B2 (en) *	2016-08-19	2024-06-20	Beone Medicines I Gmbh	Use of a combination comprising a Btk inhibitor for treating cancers
SG10201912199XA (en) *	2016-08-26	2020-02-27	Beigene Ltd	Anti-tim-3 antibodies and use thereof
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11202782B2 (en)	2016-09-27	2021-12-21	Beigene, Ltd.	Treatment cancers using a combination comprising PARP inhibitors
CA3040504A1 (en)	2016-10-14	2018-04-19	Xencor, Inc.	Il15/il15ra heterodimeric fc-fusion proteins
CN110461847B (zh)	2017-01-25	2022-06-07	百济神州有限公司	(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
KR20190137151A (ko)	2017-04-20	2019-12-10	에이디씨 테라퓨틱스 에스에이	병용 요법
WO2019001417A1 (en)	2017-06-26	2019-01-03	Beigene, Ltd.	IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
US11377449B2 (en)	2017-08-12	2022-07-05	Beigene, Ltd.	BTK inhibitors with improved dual selectivity
US11786529B2 (en) *	2017-11-29	2023-10-17	Beigene Switzerland Gmbh	Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
EP3749366A4 (en)	2018-02-09	2021-11-10	BeiGene, Ltd.	IMMUNOTHERAPY FOR UROTHELIAL CARCINOMA
GB201803746D0 (en)	2018-03-08	2018-04-25	Ultrahuman Eight Ltd	PD1 binding agents
SG11202009137PA (en)	2018-03-21	2020-10-29	Mei Pharma Inc	Combination therapy
WO2020249001A1 (zh)	2019-06-10	2020-12-17	百济神州瑞士有限责任公司	一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
CN113950327A (zh)	2019-06-10	2022-01-18	百济神州瑞士有限责任公司	口服胶囊剂及其制备方法
US20220387404A1 (en) *	2019-09-11	2022-12-08	Beigene, Ltd.	Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor

2013
- 2013-09-13 RS RS20220865A patent/RS63571B9/sr unknown
- 2013-09-13 ES ES20154386T patent/ES2927567T3/es active Active
- 2013-09-13 CN CN202011322092.7A patent/CN112552401B/zh active Active
- 2013-09-13 IL IL296026A patent/IL296026B2/en unknown
- 2013-09-13 CN CN201710208535.1A patent/CN107090041B/zh active Active
- 2013-09-13 LT LTEP20154386.5T patent/LT3702373T/lt unknown
- 2013-09-13 KR KR1020167009436A patent/KR102100419B1/ko active Active
- 2013-09-13 HU HUE13893636A patent/HUE049281T2/hu unknown
- 2013-09-13 DK DK20154386.5T patent/DK3702373T3/da active
- 2013-09-13 HU HUE20154386A patent/HUE060420T2/hu unknown
- 2013-09-13 HR HRP20221262TT patent/HRP20221262T1/hr unknown
- 2013-09-13 CA CA3080200A patent/CA3080200A1/en active Pending
- 2013-09-13 WO PCT/CN2013/083467 patent/WO2015035606A1/en not_active Ceased
- 2013-09-13 CA CA3078121A patent/CA3078121A1/en not_active Withdrawn
- 2013-09-13 ES ES13893636T patent/ES2792183T3/es active Active
- 2013-09-13 CN CN201810552595.XA patent/CN108715615B/zh active Active
- 2013-09-13 CN CN201380079581.6A patent/CN105531288B/zh active Active
- 2013-09-13 CN CN202011322081.9A patent/CN112457403B/zh active Active
- 2013-09-13 BR BR112016005408-3A patent/BR112016005408B1/pt active IP Right Grant
- 2013-09-13 PT PT201543865T patent/PT3702373T/pt unknown
- 2013-09-13 SG SG11201601844TA patent/SG11201601844TA/en unknown
- 2013-09-13 NZ NZ718643A patent/NZ718643A/en unknown
- 2013-09-13 EP EP20154386.5A patent/EP3702373B9/en active Active
- 2013-09-13 EA EA201690567A patent/EA034666B1/ru not_active IP Right Cessation
- 2013-09-13 PL PL20154386.5T patent/PL3702373T3/pl unknown
- 2013-09-13 SM SM20230039T patent/SMT202300039T1/it unknown
- 2013-09-13 JP JP2016541756A patent/JP6623353B2/ja active Active
- 2013-09-13 DK DK13893636.4T patent/DK3044234T3/da active
- 2013-09-13 PL PL13893636T patent/PL3044234T3/pl unknown
- 2013-09-13 AU AU2013400609A patent/AU2013400609B9/en active Active
- 2013-09-13 CA CA2924172A patent/CA2924172C/en active Active
- 2013-09-13 EP EP22182191.1A patent/EP4130044A1/en active Pending
- 2013-09-13 CN CN201710207300.0A patent/CN107011441B/zh active Active
- 2013-09-13 IL IL312577A patent/IL312577A/en unknown
- 2013-09-13 EP EP13893636.4A patent/EP3044234B9/en active Active
- 2013-09-13 SI SI201332011T patent/SI3702373T1/sl unknown
- 2013-09-13 MX MX2016003292A patent/MX374781B/es active IP Right Grant
- 2013-09-13 PT PT138936364T patent/PT3044234T/pt unknown
- 2013-11-10 US US14/076,214 patent/US8735553B1/en active Active
2014
- 2014-03-02 US US14/194,797 patent/US9217034B2/en active Active
- 2014-09-12 TW TW103131625A patent/TWI636995B/zh active
2015
- 2015-06-11 US US14/736,966 patent/US9834606B2/en active Active
2016
- 2016-03-09 IL IL244514A patent/IL244514B/en active IP Right Grant
- 2016-03-22 ZA ZA2016/01953A patent/ZA201601953B/en unknown
2017
- 2017-11-02 US US15/802,093 patent/US9988450B2/en active Active
2018
- 2018-05-14 US US15/978,695 patent/US10519235B2/en active Active
2019
- 2019-11-14 US US16/684,237 patent/US11673951B2/en active Active
2020
- 2020-02-14 AU AU2020201069A patent/AU2020201069B2/en active Active
- 2020-02-23 IL IL272867A patent/IL272867B/en unknown
2021
- 2021-01-21 US US17/154,696 patent/US11186637B2/en active Active
- 2021-06-21 IL IL284258A patent/IL284258B2/en unknown
- 2021-10-28 US US17/513,217 patent/US20220119524A1/en not_active Abandoned
2022
- 2022-06-15 AU AU2022204171A patent/AU2022204171A1/en not_active Abandoned
- 2022-11-04 CY CY20221100718T patent/CY1125652T1/el unknown
2023
- 2023-04-28 US US18/309,700 patent/US20230303689A1/en active Pending
- 2023-11-24 NL NL301252C patent/NL301252I2/nl unknown
- 2023-11-27 CY CY2023025C patent/CY2023025I2/el unknown
- 2023-12-04 HU HUS2300041C patent/HUS2300041I1/hu unknown
- 2023-12-07 NO NO2023045C patent/NO2023045I1/no unknown
- 2023-12-13 LT LTPA2023536C patent/LTC3702373I2/lt unknown
2024
- 2024-01-08 FR FR24C1001C patent/FR24C1001I2/fr active Active
- 2024-01-11 FI FIC20240001C patent/FIC20240001I1/fi unknown
- 2024-11-04 US US18/936,922 patent/US20250059277A1/en active Pending

Also Published As

Publication number	Publication date
CY1125652T1 (el)	2024-02-16
PL3044234T3 (pl)	2020-10-19
CN112457403B (zh)	2022-11-29
SI3702373T1 (sl)	2022-11-30
US20150079109A1 (en)	2015-03-19
EP3702373A3 (en)	2020-11-11
SG11201601844TA (en)	2016-04-28
CA3080200A1 (en)	2015-03-19
EA034666B1 (ru)	2020-03-04
CY2023025I2 (el)	2024-09-20
US20200216535A1 (en)	2020-07-09
AU2020201069A1 (en)	2020-03-05
DK3702373T3 (da)	2022-09-12
US20230303689A1 (en)	2023-09-28
AU2020201069B2 (en)	2022-03-24
PT3044234T (pt)	2020-05-27
US8735553B1 (en)	2014-05-27
KR20160044063A (ko)	2016-04-22
WO2015035606A1 (en)	2015-03-19
LTPA2023536I1 (lt)	2024-01-10
JP2016533763A (ja)	2016-11-04
FR24C1001I1 (fr)	2024-02-23
CN112552401B (zh)	2023-08-25
IL296026B2 (en)	2024-10-01
IL272867B (en)	2021-07-29
CN105531288A (zh)	2016-04-27
AU2013400609B9 (en)	2020-03-05
FIC20240001I1 (fi)	2024-01-11
IL244514B (en)	2020-03-31
IL272867A (en)	2020-04-30
IL284258B (en)	2022-10-01
AU2013400609A8 (en)	2016-07-21
EA201690567A1 (ru)	2016-08-31
JP6623353B2 (ja)	2019-12-25
US20210230274A1 (en)	2021-07-29
BR112016005408A8 (pt)	2023-01-10
PL3702373T3 (pl)	2022-12-05
BR112016005408A2 (pt)	2018-01-16
RS63571B1 (sr)	2022-10-31
CN107011441A (zh)	2017-08-04
US20250059277A1 (en)	2025-02-20
KR102100419B1 (ko)	2020-04-14
FR24C1001I2 (fr)	2024-12-13
IL284258B2 (en)	2023-02-01
NO2023045I1 (no)	2023-12-07
CA2924172A1 (en)	2015-03-19
EP3044234A4 (en)	2017-08-09
US11186637B2 (en)	2021-11-30
CA2924172C (en)	2020-06-30
EP4130044A1 (en)	2023-02-08
HRP20221262T1 (hr)	2022-12-09
ES2792183T3 (es)	2020-11-10
CN107011441B (zh)	2020-12-01
EP3044234B1 (en)	2020-03-04
AU2013400609B2 (en)	2019-11-14
CY2023025I1 (el)	2024-02-16
BR112016005408B1 (pt)	2023-03-21
US10519235B2 (en)	2019-12-31
HUE060420T2 (hu)	2023-02-28
US9988450B2 (en)	2018-06-05
CN108715615B (zh)	2020-11-27
US11673951B2 (en)	2023-06-13
EP3702373A2 (en)	2020-09-02
US20180251551A1 (en)	2018-09-06
IL244514A0 (en)	2016-04-21
AU2013400609A1 (en)	2016-05-05
LTC3702373I2 (lt)	2025-08-25
HUS2300041I1 (hu)	2023-12-28
SMT202300039T1 (it)	2023-03-17
US20150315274A1 (en)	2015-11-05
AU2022204171A1 (en)	2022-07-07
PT3702373T (pt)	2022-09-27
US9217034B2 (en)	2015-12-22
ES2927567T3 (es)	2022-11-08
EP3702373B9 (en)	2022-11-23
RS63571B9 (sr)	2023-02-28
NL301252I2 (nl)	2024-01-04
CN112552401A (zh)	2021-03-26
CN112457403A (zh)	2021-03-09
NZ718643A (en)	2020-02-28
TWI636995B (zh)	2018-10-01
CN107090041B (zh)	2018-11-16
ZA201601953B (en)	2017-06-28
IL284258A (en)	2021-07-29
EP3044234B9 (en)	2020-08-26
IL296026A (en)	2022-10-01
AU2013400609A9 (en)	2020-03-05
US20180111995A1 (en)	2018-04-26
HK1217501A1 (zh)	2017-01-13
MX374781B (es)	2025-03-06
CN105531288B (zh)	2020-12-11
US9834606B2 (en)	2017-12-05
TW201538525A (zh)	2015-10-16
HUE049281T2 (hu)	2020-09-28
IL312577A (en)	2024-07-01
CA3078121A1 (en)	2015-03-19
EP3702373B1 (en)	2022-08-24
US20220119524A1 (en)	2022-04-21
IL296026B1 (en)	2024-06-01
EP3044234A1 (en)	2016-07-20
DK3044234T3 (da)	2020-05-18
CN107090041A (zh)	2017-08-25
MX2016003292A (es)	2016-06-24
CN108715615A (zh)	2018-10-30

Publication	Publication Date	Title
HUS2300041I1 (hu)	2023-12-28	Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
IL261743B (en)	2020-11-30	and their uses 33–il antibodies against
IL261547B (en)	2019-12-31	Antibodies against pesidine and their uses
SG10201709715RA (en)	2017-12-28	Anti-b7-h5 antibodies and their uses
IL245040B (en)	2020-05-31	Antibodies against pdgfr-beta and their uses
IL243974A0 (en)	2016-04-21	Antibodies against -prlr and uses
SG10201708143QA (en)	2017-11-29	Anti-c10orf54 antibodies and uses thereof
SG11201509116VA (en)	2015-12-30	Anti-tweakr antibodies and uses thereof
SI3016977T1 (sl)	2020-03-31	Humana protitelesa proti IL-32
SG10201912310WA (en)	2020-02-27	Anti-pd1 antibodies and their use as therapeutics and diagnostics